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CHAPTER 1
AIM AND OUTLINE OF THE THESIS
The cytotoxic drug cyclopentenyl cytosine: 




Aim and Outline of the thesis
SCOPE OF THE THESIS
The aim of this study is to explore pharmaceutical aspects as well as anti-tumor activity and 
cardiotoxicity of the cytostatic drug cyclopentenyl cytosine. 
OUTLINE
The experimental cytotoxic drug cyclopentenyl cytosine (CPEC) is a pyrimidine analogue of cytidine. 
After transmembrane transport, CPEC is subsequently phosphorylated by the enzymes uridine/
cytidine kinase, nucleoside monophosphate-kinase (NMP-kinase) and nucleoside diphosphate-
kinase (NDP-kinase) to form CPEC-triphosphate (CPEC-TP), being the major metabolite [1]. CPEC-
TP is an inhibitor of cytidine triphosphate synthetase (CTP-synthetase), this enzyme catalyses the 
synthesis of the ribonucleotide cytidine triphosphate (CTP) [2,3]. Inhibition results in a decrease 
of RNA and DNA synthesis and S-phase accumulation. Moreover, a high CTP synthetase activity 
has been found in various malignant and non-malignant tissues in humans and animals [4,5], 
making this enzyme an attractive target for inhibition. Originally selected for its antiviral activity, 
most research has been done to investigate the activity of CPEC in several malignancies. In 
chapter 2 an overview of both the preclinical and early clinical studies with CPEC is given. These 
studies showed promising results on hematological malignancies and plans for phase I and II 
clinical trials were initiated.
As only the raw drug substance was available we developed a pharmaceutical formulation of 
the drug to be used in these clinical trials. A stable sterile infusion concentrate of CPEC was 
manufactured (chapter 3). 
During an early phase I trial with CPEC in solid tumors, serious cardiotoxic side effects were 
observed [6]. As these side effects seemed to be dose related, future trials would start with 
low dose CPEC and plasma monitoring of CPEC levels would become necessary. Therefore, we 
developed a sensitive and rapid HPLC MS/MS method for measuring plasma levels of CPEC and 
its metabolite cyclopentenyl uridine (CPEU) (chapter 4).
To explore the antitumor potential of CPEC in leukemia, we tested the drug in an in vivo animal 
model for human ALL using NOD/scid (nonobese diabetic/severe combined immunodeficient) 
mice (chapter 5).
Before initiating clinical trials with the experimental drug, it was necessary to further study and 
understand the mechanism of the aforementioned cardiotoxic side effects of CPEC. Cardiotoxicity 
is not uncommon among cytotoxic agents and especially the anthracyclines are well known to 
cause severe cardiotoxicity. In chapter 6 the cardiotoxicity of several cytotoxic drugs is described 
including (possible) mechanisms and preventive measures. 
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The exploration of the cardiotoxic effects of CPEC and the underlying mechanism was studied in 
both in vitro and in vivo in animal models (chapter 7). 
We further hypothesized that cardiotoxicity of cytotoxic drugs including CPEC, might have a 
genetic origin. We first performed a retrospective case control analysis in oncology patients having 
received the anthracycline doxorubicine. We investigated the differences in polymorphisms in 
several candidate genes between patients with and without anthracycline-induced cardiotoxicity 
and between cases and healthy control subjects. Furthermore, we tested in vitro in a rat 
cardiomyocyte cell line, whether doxorubicine and CPEC influenced the expression of genes that 
were suspected to be related with drug induced cardiotoxicity (chapter 8).
In chapter 9 the results of the studies presented in this thesis are interpreted and suggestions for 
further research are given. Chapter 10 provides a summary of the results.
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The experimental cytotoxic drug cyclopentenyl cytosine (CPEC) is an analogue of cytidine. Besides 
its antiviral effect, its potential use in the treatment of cancer has become an important area of 
research. CPEC is activated by intracellular phosphorylation ultimately forming its metabolite 
CPEC-TP. CPEC-TP is a non competitive inhibitor of cytidine-5’-triphosphate synthetase 
(CTP-synthetase), an important enzyme in the formation of CTP. Studies have shown that 
cancer cells have a high CTP synthetase activity, thus making CTP synthetase an interesting 
target for chemotherapy. CPEC has been preclinically studied in different malignancy models. 
In vitro results on leukemia show activity in the nanomolar range on several cell lines. However 
in vivo results are conflicting and the findings vary from increase in life span over 100% to 
only limited effectiveness. Interesting results have been obtained in colorectal and neuroblastoma 
cells. In several neuroblastoma cell lines incubation with CPEC in combination with cytarabine 
or gemcitabine has resulted in increased cell death compared to incubation with only one of the 
agents. 
CPEC has been studied in a phase I trial in patients with solid tumors. In five of 26 patients 
unexplained cardiotoxicity (extreme hypotension) occurred. 
In this overview, it is demonstrated that CPEC has an anti-cancer effect in several tumor models 
and might be a potentially useful drug in anticancer treatment. 
Keywords: Cyclopentenyl cytosine, CPEC, cancer, leukemia, cardiotoxicity
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INTRODUCTION
Nucleotides are the phosphorylated forms of nucleosides and the mature precursors of DNA 
and RNA. Because of their important role in DNA and RNA synthesis and thus in cell survival, 
nucleotides appear to be important targets in anticancer therapy. Indeed, several anticancer 
drugs, such as methotrexate or 5-fluorouracil, exert their action by interfering with nucleotide 
biosynthesis. Moreover, as cancer cells show an increased demand for nucleotides when compared 
to healthy cells, they may preferentially be targeted by these anticancer drugs. Nucleosides 
contain either a purine (adenosine or guanosine) or a pyrimidine base (cytidine, thymidine or 
uridine) [1]. The least abundant nucleoside in the cell is cytidine [2]. Cytidine 5’-triphosphate 
(CTP) can either be formed from cytidine 5’-di- and monophosphate (CDP, CMP) or from UTP 
(uridine 5’-triphosphate). The formation of CTP from UTP is catalyzed by the enzyme cytidine 
5’-triphosphate synthetase (CTP-synthetase). Fig. (1) 
Figure 1 Pyrimidine synthesis
The pyrimidine (deoxy) ribonucleotide synthesis is shown. Pyrimidine nucleotides can either be formed by de novo synthesis 
starting with glutamine or from uridine and cytidine. 
ATP: adenosine 5’-triphosphate; UTP: uridine 5’-triphosphate; UDP: uridine 5’-diphosphate; UMP: uridine 5’-monophosphate; 
CTP: cytidine 5’-triphosphate, CDP: cytidine 5’-diphosphate, CMP: cytidine 5’-monophosphate; dCDP: 2’-deoxycytidine 5’-
diphosphate, dCTP: 2’-deoxycytidine 5’-triphosphate.
The numbers represent the enymes catalyzing the conversions:
1: NDP kinase; 2: NMP kinase; 3: uridine/cytidine kinase; 4: CTP synthetase; 5: (deoxy) CMP deaminase;6: (deoxy) cytidine 








































Thus, a cell can have two different sources for CTP: CTP can be provided by the salvage pathway 
by phosphorylation of cytidine or by ’de novo’ synthesis out of UTP. An increased activity of CTP-
synthetase has been demonstrated in several malignant cell types such as hepatic carcinoma, renal 
cell carcinoma, acute lymphocytic leukemia and lymphoma [3-6]. CTP synthethase might therefore 
be an attractive target for growth inhibition of malignant cells by depletion of CTP pools. Depletion 
of CTP pools will lead to a reduction of proliferation of cells. Furthermore, as depletion of the CTP 
ribonucleotide pool also leads to a depletion of the cytidine deoxyribonucleotide (dCTP) pool, the 
balance in the ribonucleotide amount in cells will be disturbed and other deoxyribonucleotides 
than dCTP can be misincorporated during DNA synthesis, triggering apoptosis [7, 8].
The cytotoxic drug cyclopentenyl cytosine (CPEC) was designed in 1979 based on the biologically 
active and toxic nucleoside neplanocin A that was found in fermentation broth. Out of several 
purine and pyrimidine analogues of neplanocin A, CPEC was found to be the most biologically 
active compound with regard to antiviral activity and activity against murine leukemias and human 
tumor xenografts [9]. CPEC is an analogue of cytidine in which the ribose moiety is substituted 
by a carbocyclic sugar. Fig. (2) 
Figure 2 Chemical structure of CPEC 
As cytidine is hydrophilic, passive diffusion across cell membranes is not likely and nucleoside 
transporters are necessary for uptake of CPEC in cells. The equilibrative nucleoside transporters 
(ENTs) ENT1 and ENT2 both seem to be involved. Whether other nucleoside transporters 
such as the concentrative nucleoside transporter (CNT) are also involved is not clear [10]. The 
multidrug resistance proteins 4 and 5 (MRP4 and MRP5) also are suggested to be involved in 
nucleoside transport [11]. However, in human cells the transport of other nucleoside analogs 
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13]. After the facilitated diffusion through the cellular membrane, CPEC is phosphorylated [14]. 
CPEC-monophosphate is formed by uridine cytidine kinase. Nucleoside monophosphate (NMP) 
and nucleoside diphosphate kinase (NDP) are responsible for the further phosphorylation 
ultimately leading to CPEC triphosphate (CPEC-TP). Fig. (3) 
Figure 3 Metabolism and proposed mechanism of action of CPEC
After intra-cellular transport CPEC is phosphorylated to CPEC-TP. CPEC-TP inhibits CTP synthetase (4) resulting in CTP depletion.
CPEC can be either cleared as unchanged drug or deaminated to its metabolite CPEU by the enzyme cytidine deaminase (5). 
CPEC-MP: CPEC-monophosphate; CPEC-DP: CPEC-diphosphosphate; CPEC-TP: CPEC-triphosphate
The numbers represent the enymes catalyzing the conversions:
1: uridine/cytidine kinase; 2: NMP kinase; 3: NDP kinase; 4: CTP synthetase; 5:cytidine deaminase 
After incubation with CPEC, Moyer et al found strong inhibition of the formation of [3H]-CTP from 
[3H]-uridine in L1210 cells. This suggested inhibition of CTP synthethase by CPEC [15]. In K562 
cells CPEC also induced erythroid differentiation in presence of p38 MAP kinase activity [10]. 
CPEC-TP was found to be mainly responsible for this effect as µM-range concentrations of CPEC-TP 
were able to inhibit CTP synthetase, whereas CPEC, CPEC-MP and CPEC-DP showed no inhibition 
at all or only at much higher concentrations [16]. Cyclopentenyl uridine (CPEU), the deamination 
product of CPEC, seems to be the major metabolite of CPEC with almost no cytotoxic effects [14, 17]. 
The observed preclinical effects of CPEC suggest a potential use as an anti-cancer agent. In this 
review an overview of both the preclinical and early clinical studies undertaken with CPEC will 
be given. Studies were selected by Medline search using the keywords [cyclopentenyl cytosine], 

















PRECLINICAL ACTIVITY OF CPEC
In vitro antiviral activity
Like several other pyrimidine nucleoside analogues, CPEC has both antiviral and anti-tumor effects. 
The mechanism of action of the antiviral effect is believed to be based on the CTP depletion 
caused by CPEC. Apparently CTP synthetase interacts as a host cell enzyme that may be used as 
a target enzyme for antiviral agents. In in vitro assays, CPEC showed antiviral activity against a 
broad range of viruses (e.g. herpes simplex, polio, rhino, influenza, yellow fever, West Nile) at a 
wide range of concentrations. An IC50 of 0.02 µg/ml (80 nM) was observed for vaccinia viruses 
[18]. This concentration is comparable to concentrations at which anti-tumor effect is observed. 
However, most of the viruses were inhibited at concentration of 0.1 µg/ml (400 nM) and higher. 
The in vitro assays for antiviral activity were conducted on resting confluent cells whereas 
exponentially growing cells were used for the anti-tumor assays. Exponentially proliferating cells 
seem to preferentially use the ‘de novo’ synthesis of CTP (involving CTP synthetase) thereby 
making them more sensitive to CPEC. 
Antiviral activity has not yet been established in animal models. Whether it is possible to create an 
antiviral effect without toxic effects on rapidly growing cells is therefore not clear yet [18-22].
Activity in malignancies
LEUKEMIA, IN VITRO STUDIES
In MOLT-4 lymphoblasts CPEC concentrations between 20 nM (72 hr incubation) and 75 nM (16 
hr incubation) were able to reduce proliferation rates by 50% [14]. In the human promyelocytic 
leukemia cell line HL-60, DNA synthesis was almost completely inhibited after 24 hrs incubation 
with 30 nM CPEC. At this concentration RNA synthesis was less reduced (approximately 30% 
reduction) [23]. In cells from pediatric patients with acute lymphocytic and acute non-lymphocytic 
leukemia, incubation with CPEC caused a dose dependent depletion of CTP [24, 25]. CPEC was 
also used in combination with cytarabine and analogues. Cytarabine must be phosphorylated 
before it can be incorporated into DNA and exert its cytotoxic effect. The rate limiting enzyme in 
this process is deoxycytidine kinase (dCK). The activity of dCK is regulated and can therefore be 
inhibited by deoxycytidine-triphosphate (dCTP). De novo synthesis of dCTP occurs by reduction 
of cytidine 5’-diphosphate to 2’-deoxycytidine 5’-diphosphate by ribonucleotide reductase and 
subsequent phosphorylation to dCTP by nucleoside 5’-diphosphate kinase. Depletion of CTP pools 
leads to a decrease in dCTP and could have a positive influence on incorporation of cytarabine. 
Incorporation of cytarabine into DNA was increased with by 41% in a human T-lymphoblastic cell 
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line (MOLT-3) after preincubation with CPEC (100nM), followed by incubation of cytarabine (2nM) 
[26]. Similar results were obtained with the deoxycytidine analogue 5-aza-2’-deoxycytidine (DAC) 
and gemcitabine in combination with CPEC in HL60 cells [27, 28] and MOLT-3 cells [28]. 
LEUKEMIA, IN VIVO STUDIES
Moyer et al inoculated mice with the lymphoid leukemia cell line L1210 (1x105 cells). Several 
dose regimens were applied; from 10-50 mg/kg as a single dose to 1-6 mg/kg/day for 5 days 
and 1 mg/kg/day for 9 days. All mice, including those receiving saline, died within 20 days after 
inoculation. An increase in life span (ILS) of 111-122% was observed after 9 days of treatment 
with 1 mg/kg CPEC. The other regimens were either too toxic (> 3 mg/kg for 5 consecutive days) 
or ineffective (single dose up to 50 mg/kg) [15]. These results correspond with other experiments 
in L1210 inoculated mice [29]. Although with a broader range in ILS (73-129%), increase in life 
span was also reported for mice inoculated with P388 lymphocytic leukemia [15]. Combination 
treatment of the palmitate derivative of cytarabine and CPEC in mice inoculated with L1210 cells 
(with a subpopulation resistant to cytarabine), resulted in an increase in lifespan when compared 
to single treatment with the palmitate derivative only. However, since toxicity of the combination 
was more severe than while using monotherapy, the maximum tolerated dose (MTD) of palmitate 
cytarabine as a single agent was not achieved. When the MTD in both regimens was compared 
there were no longer significant differences in survival [30]. 
NEUROBLASTOMA
At concentrations similar to those at which anti-leukemic activity was observed, CPEC was also 
active on SK-N-BE(2)-C neuroblastoma cells [7, 31]. Moreover, coincubation of CPEC (50-250 nM) 
and cytarabine (37.5-500 nM) increased the cytotoxic effects of cytarabine [32]. Preincubation 
of CPEC (100 nM) followed by the deoxycytidine analogue gemcitabine (50 nM), also resulted in 
increased cell death for 13 of the 15 neuroblastoma cell lines when compared to a set up in which 
incubation with only gemcitabine took place [33]. 
BRAIN TUMORS 
CPEC has demonstrated in vitro activity against human glioblastoma cells [34]. However, CPEC 
shows relatively poor penetration of the blood brain barrier. In mice inoculated intracerebrally 
with leukemic L1210 cells intraperitoneal administration of CPEC was less effective than in mice 
inoculated intraperitoneally or subcutaneously with L1210 [18]. It can be concluded that CPEC 
does not appear to be a suitable agent to be used in brain tumors. However, the poor penetration 
of CPEC intracerebrally might be overcome by direct intratumoral administration of the drug. 
In one study CPEC (200 µM by continuous infusion in 4 weeks) was directly infused into brain 
gliosarcomas in rats [35]. Rats treated with CPEC survived 32 days versus 25 days for rats 
treated with saline (p<0.0001). In tumor tissue CTP was depleted to a much greater extent 
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than in the adjacent tissues, indicating that exposure to CPEC was restricted to the infused area. 
The absence of systemic exposure might indicate that intratumoral administration results in less 
toxic effects. Whether intratumoral administration of CPEC is feasible in humans needs to be 
investigated further. 
COLORECTAL CARCINOMA
Growth inhibitory effects of CPEC have been demonstrated in four different human colorectal cell 
lines (HCT 116, SNU-C4, NCI-H630 and HT-29) [36, 37]. The IC50 values vary between 10 
and 60 nM after 72 hours of incubation (HCT 116, SNU-C4 and NCI-H630) and 460 nM after 
24 hours of incubation (HT-29). For an in vivo study, mice were inoculated with HT-29 cells. 
Although CPEC treatment did not fully halt tumor growth, it was shown that the increase was only 
one third of the growth measured in controls [38]. Combination treatment of CPEC with cisplatin 
was examined in vitro and in vivo (athymic mice) using HT-29 cells [39]. Cisplatin treatment 
alone did not result in significant tumor reduction; this is in line with clinical data indicating 
limited activity of cisplatin in colorectal carcinoma as a single agent [40]. However, when cisplatin 
(4 mg/kg Q7Dx3) was combined with CPEC (1.5 mg/kg, QDx9) tumor volume was reduced to 
16% of the volume in the control group. Treatment with CPEC alone resulted in a reduction of 
40%. However, when treatment was stopped, tumor growth was detected again, indicating a 
cytostatic and not cytocidal effect [39]. 
IN VITRO RESISTANCE
Since in clinical oncology drug resistance is a frequent cause of treatment failure, attempts have 
been made to investigate CPEC resistance in vitro in MOLT-4 lymphoblasts and L1210 leukemic 
cells [41,42]. In the resistant MOLT-4 lymphoblasts, CPEC-TP was formed 10-100 fold lower 
than in the wild type cell line. Resistance could be partly explained by a decreased activity of the 
enzyme uridine-cytidine kinase which catalyses the first phosphorylation step of CPEC. However, 
this was not the only possible explanation as concentrations of CPEC-TP that were cytotoxic in 
the wild type cell line, were found not cytotoxic in the resistant cell line and high CTP levels were 
found in the resistant cells. Therefore it could be concluded that there was another mechanism at 
work and it is believed that this could be a change in CTP-synthetase activity [42, 43]. This second 
mechanism was confirmed in leukemic cells, where an increased activity of CTP-synthethase was 
found in the resistant cells without a change in uridine-cytidine kinase [42]. 
An increased activity of the enzyme that is responsible for the deamination of CPEC (cytidine 
deaminase, CDD, Fig.3) to its metabolite CPEU could be a third cause of resistance. By 
deaminating cytosine nucleosides and analogs, CDD prevents the accumulation of the intracellular 
active triphosphates. Overexpression of CDD has been associated with protection of cells from 
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cytarabine and gemcitabine [44]. A fourth hypothetic mechanism might be found in the transport 
over the cellular membrane. Huang et al showed that CPEC diffusion is facilitated by ENT1 and 
ENT2 [10]. Changes in these transporters might influence the uptake of CPEC in the cell. Nitric 
oxide has been able to reduce ENT1 promotor activity in human fetal endothelium [45] and during 
hypoxia ENT1 function seems to be repressed, making hypoxic tumors potentially susceptible 
for reducing CPEC uptake [46]. It is not clear whether other transporters involved in nucleoside 
transport such as CNT and MRP4 and MRP5 are involved in CPEC transport. If CPEC transport 
would not be mediated by other nucleoside transporters, tumors predominantly expressing CNT 
might be resistant to CPEC. However, there are little data as yet about nucleoside transporter 
expression among tumors. What is clear however, is that leukemia cells seem to have both an ENT 
and a CNT transporter function [47]. 
Although it is unclear whether in vitro created resistance is a good model for future in vivo 
resistance, the results described here might be a useful tool in understanding resistance in vivo. 
MODULATION OF CYTOTOXIC EFFECT 
The deamination product of CPEC, CPEU was found to protect cells against the cytotoxic effects of 
CPEC [17]. Coincubation of a 100-fold higher concentration of CPEU (50 µM) with CPEC (0.5 µM) 
resulted in 50% survival of cells, whereas only 10% survived with 0.5 µM CPEC alone. Addition of the 
CPEU after incubation of CPEC diminished the increase in survival. An inhibition of uridine-cytidine 
kinase was suggested to be responsible for the ‘rescue’ by CPEU. This might result in decreased 
concentrations of CPEC-TP as uridine-cytidine kinase is necessary for the first phophorylation step 
of CPEC. Clinical implications of this effect are not to be expected as CPEU levels in humans did 
not exceed those of CPEC [48]. Cytidine might be a more useful modulator of CPEC activity. In 
vitro experiments in leukemic and colorectal cells have shown an increase in survival even after 
delayed administration of cytidine to CPEC treated cells [14, 37]. Combination treatment of CPEC 
and cytidine in mice inoculated with L1210 cells resulted in less toxicity without significant changes 
in increase in life span [29]. Competition for transmembrane transport and phosphorylation might be 
responsible for the observed effects. It was suggested that by delaying the administration of cytidine a 
first rapid effect of CPEC could be induced, followed by a rescue of toxic effects of cytidine [14]. 
In neuroblastoma cells retinoic acid attenuated the effects of CPEC and resulted in a 5 to 20 fold 
increase of IC50 of CPEC. As both agents show activity against neuroblastoma, this might have 





Zaharko et al studied the pharmacokinetics of CPEC in mice, rats and beagle dogs. The 
plasma concentration was best described by a three compartment model consisting of a central 
compartment (extracellular fluid) and two cellular compartments. After distribution a rapid first 
elimination phase was observed followed by a long terminal half-life which probably is caused 
by the retention of CPEC as CPEC-TP and subsequent slow release of CPEC from CPEC-TP by 
phosphatases. CPEC was mainly cleared into urine unchanged for all different species studied 
[50]. In contrast to these data, clearance of CPEC in nonhuman primates occurred primary by 
deamination by cytidine deaminase to the inactive metabolite CPEU. Only 20% of the total dose 
was excreted as an unchanged drug. The deamination resulted in a lower total exposure of CPEC 
(expressed by a lower AUC) in monkeys compared to an equivalent dose of CPEC in rodents. CPEC 
was rapidly eliminated with a terminal half life of 20 to 60 minutes. Two hours after a single 
dose of CPEC, CPEU levels exceeded CPEC levels more than 40 fold. However, after continuous 
infusion steady state concentrations of CPEU varied no more than 4 times the CPEC levels, 
suggesting a saturable metabolism. The differences between rodents and nonhuman primates 
may be explained by the activity of cytidine deaminase. Rats have an almost non-existent cytidine 
deaminase, whereas high levels can be found in nonhuman primates [51]. Results from these 
studies have been used to determine the dose of CPEC to be used in clinical trials.
Human 
Data from two patients that received an intravenous test dose of 24 mg/m2 showed two phases 
of rapid elimination of CPEC from the plasma (half-lives 8 and 100 minutes respectively). CPEC 
could still be detected 24 hrs after the end of the infusion, suggesting the existence of a third phase 
resulting in a long terminal elimination half-life. Measurements from 26 patients receiving a 24 
hrs continuous infusion of CPEC confirmed these results. During the 24 hrs-infusions the steady 
state plasma levels increased linearly with increasing doses and steady state was achieved after 
approximately 12 hrs of infusion. Plasma concentrations of CPEU were below CPEC levels [48]. 
These pharmacokinetic data are in line with the results from preclinical studies in rodents [50]. 
Humans are reported to have less cytidine deaminase than nonhuman primates [51] Deamination 
therefore seems to be not as important in clearance as it is in the case of nonhuman primates and 
CPEC is mainly eliminated as an unchanged drug in the urine.
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TOXICOLOGY
Animal 
Toxicity of CPEC seems to be dose and schedule related. Mice can tolerate single doses of CPEC up 
to 50 mg/kg without showing any signs of toxicity [15]. However, more than 2 mg/kg for at least 9 
days results in weight loss [15, 29]. Tolerability of CPEC also seems to differ among the different 
species. No toxicity of CPEC was detected in rats treated with 2 mg/kg/day for a period of four 
weeks [35]. The difference in tolerability between species was confirmed by other experiments 
showing a more toxic effect of CPEC on mice than on rats [52]. The high cytidine levels or almost 
absent levels of cytidine deaminase in rats are thought to account for these differences. Single 
doses of CPEC in beagle dogs (3-40 mg/kg) resulted in oral lesions and a decrease in body weight. 
Bone marrow and gastro-intestinal epithelium were also affected [53]. 
Human
In a phase I study in 26 patients with solid tumors granulocytopenia and thrombocytopenia were 
reported as dose limiting toxicities in 2 of 3 patients during the first 3 weeks after a 24-hour infusion 
of CPEC at a dose of 5.9 mg/m2 per hr, whereas non dose limiting were vomiting, mucositis and 
diarrhea. The majority of patients had colorectal cancer and most of them were heavily pretreated 
with chemo- and/or radiotherapy. All but one patient had documented disease progression prior to 
entering this study. The median time to treatment failure was > 3 months in 11 patients (42%), 
which is compatible with an active antitumor agent. However, the most severe adverse effect was 
a severe hypotension which occurred in 5 patients at the lower dose levels of 3.5 and 4.7 mg/m2 
per hr and resulted in death in two of them. None of the patients experiencing the hypotension 
was dehydrated. Hypotension occurred 24 to 48 hours after the end of infusion and seemed to be 
dose related. No hypotensive episodes or other important toxicity occurred at doses equal or below 
2.5 mg/m2 per hr. Laboratory results from the hypotensive patients showed a pattern consistent 
with hypoperfusion (hypoxemia, increased creatinine and metabolic acidosis). The echocardiograms 
showed left ventricular contraction but no signs of pericardial effusion. Post mortem examination on 
one of the two deceased patients revealed subendocardial necrosis and minimal pericardial effusion. 
From the other patient it was known that there was no prior cardiac history [48]. The mechanism of 
these hypotensive episodes was not clarified. Between those patients that did experience hypotension 
and those that did not there were no differences in the CPEC-CPEU ratio. Moreover, inhibition of 
CTP synthase activity seemed to be similar for all patients. These findings suggested that there 
were no differences in uptake or excretion between the patients. Influence of CPEC on cardiolipin 
metabolism (a major phospholipid in the heart) [54, 55] or a preference in the cardiomyocytes for 
CTP synthesis by the salvage pathway via CTP synthetase, were proposed mechanisms. 
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CONCLUSION AND PLACE IN THERAPY 
The mechanism of action of CPEC is supposed to involve inhibition of the enzyme CTP-synthetase. 
As a high activity of this enzyme has been observed in several malignancies [3-6], CTP-synthetase 
seems to be an interesting target for a wide range of tumors. 
The effects of CPEC have been studied most extensively in leukemia. Current therapy for leukemia 
has improved survival, however, e.g. ALL is still associated with a poor prognosis and new agents 
are warranted. Therapy with CPEC in humans with solid tumors resulted in hematotoxic side 
effects [48], suggesting that leukemic cells might be sensitive to CPEC. Indeed several preclinical 
studies show anti-leukemic activity of CPEC. Moreover, it might be worthwhile to investigate the 
use of CPEC in combination with other drugs for the treatment of ALL, like cytarabine. Other 
promising areas might be colorectal carcinoma and neuroblastoma. For colorectal carcinoma 
addition of CPEC to currently used therapy combinations (e.g. oxaliplatin with fluorouracil and 
the VEGF inhibitor bevacizumab) could be of interest. As the use of CPEC in neuroblastoma has 
only been studied in vitro, testing the drug in an animal model will be necessary to confirm the 
in vitro data. Based on the in vitro data it might be interesting to study the effect of CPEC on 
neuroblastoma in combination with other drugs, like gemcitabine.
The observed cardiotoxic side effects in the Phase I trial remain a point of concern and care should 
be taken if the drug is to be administrated in future clinical trials. As the toxicity seemed to be dose 
related, a restriction in the maximum administrated dose will have to be considered in these trials. 
Moreover, close monitoring of plasma levels will be necessary to check whether the administrated 
dose does not lead to plasma levels at which cardiotoxicity occurred in the Phase I trial. 
The reviewed data in this manuscript illustrate an anti-cancer effect of CPEC in several tumor 
models and suggest that CPEC might be a potential drug in anticancer treatment. Further study is 
needed, however, until now only preclinical data on efficacy are available and it is as yet unclear 
whether the same anti-cancer effect of CPEC can be reached in humans. 
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This paper describes the formulation and quality control of an aqueous sterilized formulation of the 
experimental cytostatic drug cyclopentenyl cytosine (CPEC) to be used in Phase I/II clinical trials. 
The raw drug substance was extensively tested. A High Performance Liquid Chromotography 
(HPLC) method was validated for the quality control of the formulated product. The aqueous 
formulation was found to be stable for at least 2 years at 2-8ºC. Sterilization (15 min at 121 
ºC) showed no influence on drug stability. The results show that CPEC can be formulated in an 
aqueous solution. The described HPLC method is a useful tool in the pharmaceutical quality 
control.
Keywords: Cyclopentenyl cytosine, CPEC, Cytostatic drug, Formulation, Quality control
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INTRODUCTION
The experimental cytotoxic drug cyclopentenyl cytosine (CPEC, Fig. 1) is a pyrimidine analogue 
of cytidine, currently entering phase I/II trials in recurrent leukemia. After transmembrane 
transport, CPEC is subsequently activated by phosphorylation by the enzymes uridine-cytidine 
kinase, nucleoside monophosphate-kinase (NMP-kinase), and nucleoside diphosphate-kinase 
(NDP-kinase) respectively to form CPEC-triphosphate (CPEC-TP), the major intracellular 
pharmacologically active metabolite. Cyclopentenyl cytosine-triphosphate (CPEC-TP) is an 
inhibitor of cytidine triphosphate-synthetase (CTP-synthetase) resulting in inhibition of RNA and 
DNA synthesis and leading to S-phase accumulation (Fig. 2). So far, CPEC pharmacokinetics and 
toxicity have been studied in a single phase I trial in 26 patients with solid tumors (in majority 
colorectal carcinoma). Dose limiting toxicity was of hematological nature. However, the most 
severe adverse drug reaction was cardiovascular: six episodes of hypotension occurred in five 
patients (dose range: 3-4.7 mg/m2/h) and two patients, treated with the highest applied dose 
(4.7 mg/m2/h), had a fatal hypotensic episode [1]. In the early phase I study, a lyophilized 
formulation of CPEC dispensed by the National Cancer Institute (NCI, Bethesda, Maryland, USA), 
was applied. In the present article we describe the development of an aqueous drug formulation of 
CPEC for intravenous use in our phase II trial and methods for the pharmaceutical quality control 
of the raw drug substance and formulated product.
Figure 1 Chemical Structure of CPEC.
The mechanism of the cardiotoxic effects remains yet unclear [2] and has hampered the initiation 
of phase II studies with CPEC. In various human and animal leukemia models, antitumor activity of 
CPEC was demonstrated at relatively low drug concentrations [3,4]. Following these observations, 
we recently have initiated a phase II study of low dose CPEC in adults with hematological 
malignancies (acute myeloid leukemia, acute lymphocytic leukemia, and myelodysplastic 
syndrome) under strict cardiac monitoring. Furthermore, a phase I/II trial in pediatric patients 











Cyclopentenyl cytosine (CPEC) (NSC375575, lotnr. BK-09-142) was kindly provided by 
the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of 
Cancer Treatment of the NCI. For the manufacturing, 10 ml glass vials (DIN-I, Aluglas, Uithoorn, 
Netherlands) were used to contain the product solution and sterile 0.2 µm cellulose acetate filters 
(Millipore, The Netherlands) for filtration. Water for injections was manufactured in house (conform 
PhEur) (Department of Pharmacy, Academic Medical Centre, Amsterdam, The Netherlands).
The following analytical grade chemicals were used for quality control: methanol (Labscan Ltd, 
Ireland); ammoniumacetate (Merck, Darmstadt, Germany), 5- methylcytosine (Sigma-Aldrich, 
Munich, Germany), and tetrahydrofuran (THF, Merck, Darmstadt, Germany).
Figure 2 Mechanism of Action of CPEC. 
In the figure a part of the pyrimidine (deoxy) ribonucleotide synthesis is shown. The enzyme CTP-synthetase is inhibited 
by CPEC-TP, leading to depletion of the CTP pool and subsequently inhibtion of DNA and RNA synthesis. CPEC-TP: 
CPEC-triphosphate; UTP: Uridine-triphosphate; UDP: Uridine-diphosphate; UMP: Uridine-monophosphate; CTP: Cytidine-
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Quality Control of Drug Substance
The raw active substance was stored at 20ºC in a glass airtight container. The National Cancer 
Institute (NCI) initially performed identity and purity tests on each lot of the bulk drug substance 
(personal communication, Dr. R. Vishnuvajjala). The general tests performed by the NCI consisted 
of appearance, melting point, optical rotation, and elemental analysis. Conformity was further 
tested with UV (ultra violet), IR (infrared), MS (mass spectrometry), H-1, and C-14 NMR (nuclear 
magnetic resonance). Furthermore, the drug substance was chromatographically tested [thin layer 
and reverse phase high performance liquid chromatography (RP-HPLC)].
Before drug formulation, the following quality control tests on the raw material were performed 
(Laboratory of Clinical Pharmacy & Toxicology, AMC, Amsterdam).
IDENTITY
Identity was confirmed by infrared spectroscopy (FTIR-8201PC Shimadzu Corp., Japan), 
LC-MSMS product ion scan, concentration app. 100 µg/ml and UV-VIS spectroscopy (UV-2410 
PC, Shimadzu, 8.4 mg/ml in H2O).
LOSS ON DRYING
An amount of approximately 100 mg CPEC (precisely weighed) was dried for 4 h at 100-105ºC 
in a pre-dried glass vial (1 h at 100-105ºC).
HEAVY METALS
Presence of heavy metals was not tested as no heavy metals that can be detected by the USP 
method were used in the synthesis of CPEC.
QUALITATIVE DRUG ANALYSIS
Analysis of impurities of the drug substance and content of the product was performed using 
an RP-HPLC equipped with a UV photo diode array detector (Jasco MD 1510 Multiwavelength 
detector, Jasco Corp., Japan), an autosampler (Jasco AS 1555 Intelligent sampler), and a pump 
(Jasco PU 1580 HPLC pump). Chromatograms were processed using Empower software (Waters, 
Netherlands). Separation was achieved using a Supelcosil LC-18 column (25 cm x 4,6 mm, 
5 µm) (Supelco, Sigma-Aldrich, Netherlands). The method was originally developed at the 
NCI. The mobile phase consisted of 2% methanol in 0.1 M ammoniumacetate at a flow rate of 
1.0 ml/min. The detection wavelength was 276 nm. The injection volume was 20 µl and a run time of 
20 min was employed. A concentration of 24 mg CPEC/l and 50 mg CPEC/l was used for analysis 
of impurities of the drug substance. A concentration of 4.5 mg/l was used for the analysis of 
content of the product. The internal standard used was 5-methylcytosine (5 mg/l).
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Validation of HPLC Procedure
Validation of the method of analysis was performed according to good clinical laboratory practice 
(GCLP) guidelines as follows.
DETERMINATION OF THE SELECTIVITY AND SPECIFICITY
Impurities or degradation products were required to elute separately from CPEC in order to 
assess possible impurities. Cytosine is used in the synthesis of CPEC, and dideoxycytidine and 
cytarabine have a strong structural relationship with CPEC. Therefore, cytosine, dideoxycytidine, 
and cytarabine were examined. In order to test if degradation products could be detected and 
separated, samples of CPEC were exposed to extreme temperature (48 h at 120ºC), acid and 
alkaline conditions, respectively. All substances were dissolved in water and injected onto the 
HPLC system. To evaluate proper separation from CPEC, the resolution factor (R) between CPEC 
and the nearest peak (internal standard, 5-methylcytosine) was determined. To obtain a separation 
of peaks of at least 99.7% for quantification, a resolution factor of at least 1.5 was required.
DETERMINATION OF RANGE
The final product (CPEC, 4.5 mg/ml) was diluted to obtain a concentration suitable for quantification 
with HPLC. A quantification range of 75% and 125% of this concentration was chosen.
ACCURACY AND RECOVERY
As the final product will be dissolved in an aqueous solution, which will only have to be diluted 
for analysis, no tests on accuracy and recovery were performed.
REPEATABILITY AND INTERMEDIARY PRECISION
Repeatability was tested by analyzing a reference sample within one day (n = 6) and on six 
different days. Repeatability was determined for four different concentrations (90%, 95%, 105%, 
and 110% of the nominal product concentration). Concentrations were calculated relative to the 
100% value (“one point calibration”). The mean, standard deviation, and variation coefficient 
were determined of each series. Repeatability variation coefficients were considered acceptable 
below 5%. Intermediary precision was performed in the same way as the repeatability but with 
varying equipment, technician, and eluent lot.
LINEARITY
Reference samples with 75%, 90%, 95%, 100%, 105%, 110%, and 125% of the declared 
product concentrations were analyzed on six different days. A calibration line was calculated 
for each different day. Each reference sample was recalculated on the calibration line obtained 
with the other reference samples of that day. The obtained individual concentrations were not 
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allowed to differ more than 5% of the nominal values. Linearity (y = ax + b) was tested with the 
“goodness of fit test” (GOF-test) using SPSS software (version 9.0). An F-value of the test of at 
least 7.71 and an r2 value of >0.990 were considered acceptable.
ROBUSTNESS AND SUITABILITY OF THE METHOD
In order to test whether the method could be used for the final (sterilized) product, two 
reference samples were sterilized (15 min at 121ºC) before analysis. The following changes in 
chromatography conditions were tested in order to investigate whether the separation could be 
further optimized: change of the MeOH (Methanol) concentration in the mobile phase (1% instead 
of 2%) and addition of THF.
Drug Formulation
Cyclopentenyl cytosine (CPEC) was dissolved in purified water at a concentration of 4.5 mg/ml 
(dry weight, determined one day before production). The dissolved product was filtered through 
a 0.2 µm membrane filter in a class A laminar flow safety cabinet with class D background 
environment. Ten milliliter sterile vials were filled with 2.0 ml of the product solution. Vials were 
sterilized (15 min 121ºC) in a heat water autoclave. As initially little information was available on 
the stability of CPEC in an aqueous solution, the vials were stored at 4ºC after sterilization.
QUALITY CONTROL OF PRODUCT
Before the product could be used, several analyses were performed. Labeling, volume, pH, and 
physical appearance had to comply with product specifications. Sterility was assured by parametric 
release. Content was assessed in duplo by using the above described HPLC method.
SHELF LIFE EXPERIMENTS
In order to test whether the content of the product remained stable until the end of the planned 
expiration date, two different batches of the product were analyzed on several time points up to 




Quality Control of Drug Substance
IDENTITY
Infrared spectroscopy showed a spectrum consistent with the chemical structure and with results 
obtained earlier (certificate of analysis, NCI). The UV-VIS spectrum showed a major absorption 
band with a maximum at 276 nm which corresponded with earlier data. The mass spectrum also 
complied with the chemical structure of CPEC (Fig. 3).
Figure 3 Mass Spectrum of CPEC
LOSS ON DRYING
Loss on drying was determined on two samples; the loss on drying was respectively 9.07% and 
9.93%, with a mean loss of 9.5%.
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Validation of the HPLC Method
DETERMINATION OF THE SELECTIVITY AND SPECIFICITY
Cyclopentenyl cytosine (CPEC), dideoxycytidine, 5-methylcytosine, and cytarabine eluated 
well separated from the column. The resolution between CPEC and the internal standard (5-
methylcytosine) was 35 which is above the limit of acceptance of 1.5. A representative 
chromatogram of a reference sample containing CPEC and the internal standard is shown in Fig. 
4. The chromatogram of the sample which was kept 48 h at 120ºC, showed a minor unidentified 
peak next to the CPEC peak, probably indicating a degradation product. The chromatograms of 
the samples submitted to acid and alkaline conditions were similar to the unexposed reference 
sample.
Figure 4 Characteristic HPLC Chromatogram of CPEC. 1: CPEC. (4.5 mg/l); 2: 5-methylcytosine 
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Dilutions of the final product to 75% (3.375 mg/l) and 125% (5.625 mg/l) of the declared 
product concentration could be measured and quantified.
REPEATABILITY AND INTERMEDIARY PRECISION
The repeatability and intermediary variation coefficients for all the determined concentrations 
(90%, 95%, 105%, and 110%) were less than 3%. Mean, standard deviation, and variation 
coefficients for the intra (six in one day) and inter (six different days) day repeatability are shown 
in Table 1.
Table 1 Repeatability and intermediary precision of HPLC method
Mean concentration (%) Standard deviation Variation coefficient (%)
90% repeatability intermediary repeatability intermediary repeatability intermediary
Within 1 day 91.07 89.50 0.58 2.04 0.63 2.28
6 days 90.37 91.41 0.91 1.02 1.01 1.12
95%
Within 1 day 93.69 94.84 0.49 2.00 0.53 2.07
6 days 95.41 95.54 1.34 0.64 1.40 0.67
105%
Within 1 day 104.82 105.10 2.12 1.21 2.03 1.14
6 days 103.99 105.66 1.32 1.09 1.27 1.03
110%
Within 1 day 109.24 111.17 2.31 2.16 2.11 1.94
6 days 109.06 110.74 1.48 1.33 1.36 1.21
LINEARITY
All seven-point calibration curves of CPEC were linear with a mean correlation coefficient of 0.994 
(standard deviation 0.004) and F-values above 7.71. The maximum difference of the individual 
concentrations from the nominal concentrations was 1.31% (see Table 1).
ROBUSTNESS AND SUITABILITY OF THE METHOD
The chromatograms of the sterilized product were not different from the non-sterilized standard 
solution. Changes in chromatographic condition did not further improve the separation (data not 
shown).
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Formulation of Product
Two lots (batch size: 100 vials) were produced and could be released for clinical use after quality 
control. Shelf life experiments showed no deterioration in CPEC concentration (Table 2) at 24 
months after production. The lowest concentration after two years in the two lots was 97.2 and 
99.5%, respectively, of the declared concentration. After 18 months the concentration seemed 
to increase. A possible cause for the assumed increase could be analytical and probably due to 
insufficient drying of the standard used in the HPLC method. The results at 20 and 24 months 
seemed to confirm this assumption as the concentrations remained then within 10% of the 
declared value.
Table 2 Shelf life experiment
month s of 
storage
Content CPEC batch 1 (% of declared 
concentration
Content batch 2 (% of declared 
concentration, mean of two assays)
0 102.0 [101.66-102.30] 99.3 [99.3-99.3]
2 99.7 [99.6-99.7] *
9 99.5 [99.0-99.9] 97.2 [96.4-98.0]
11 101.3 [101.32]** 102.4 [102.38]**
18 112.6 [112.2-113.0] 109.4 [109.2-109.6]
20 106.5 [106.1-107.0] 108.1 [107.7-108.4]
24 108.3 [106.2-111.5] 101.2 [98.1-104.3]
The percentages in the table represent the mean of two assays, between brackets the individual values are given. 
*Not determined




In an early and single Phase I trial of CPEC in patients with solid tumors, a lyophilized formulation 
of CPEC was used. A drawback of this approach is that lyophilization facilities are required for drug 
formulation and once formulated the presentation form needs reconstitution before administration. 
However, in case of labile compounds, lyophilization permits much longer storage as compared 
to aqueous solutions. As pilot experiments suggested good stability of CPEC in aqueous solutions, 
we investigated whether the production of an aqueous CPEC drug formulation was feasible. We 
started our experiments with testing the raw drug substance. As no Pharmacopoeia monograph is 
available, quality control criteria were absent and a set of specifications and analytical methods 
were determined in our laboratory based upon information from the NCI. The chosen HPLC 
method was developed for pharmaceutical quality control and not for the determination of CPEC 
concentrations in biological specimens such as serum. This implicates that stability indicating 
performance and the precision at the declared product concentration were considered more 
relevant than e.g., the limit of detection. The method was validated and found to be precise, linear, 
and stability indicating. The HPLC method was accepted for use in pharmaceutical quality control 
of both the raw active substance and the product. The initial expiration date was set at three years 
after production and actual parent drug concentration was frequently monitored at a shelf life 
experiment during storage at 4ºC. Currently, after two years of shelf life, the CPEC concentration 
remained above 97% of the declared concentration. Measurements will be continued for the 
remaining storage time. Before administration the product can be further diluted with standard 
infusion solutions. There is no reason to assume that the product will be less stable after dilution. 
However, as the product does not contain preservatives, a short period of usage will be advised 
for microbiological reasons. This study shows that CPEC can be formulated in an aqueous solution 
and stored for at least two years at 4ºC. The described HPLC method is a useful tool in the 
pharmaceutical quality control of the drug substance and product.
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The cytotoxic drug cyclopentenyl cytosine (CPEC) is currently being investigated in early clinical 
trials. Monitoring of plasma levels is required for pharmacokinetic analysis and management of 
toxicity. This paper describes the analysis of CPEC and CPEU in plasma by HPLC-electrospray 
ionization tandem mass spectrometry. The calibration curves for CPEC and the metabolite 
cyclopentenyl uracil (CPEU) were linear up to 10 µM with correlation coefficients of 0.997 (SD 
= 0.002, n = 10) and 0.997 (SD = 0.004, n = 10), respectively. The detection limit for CPEC 
was 0.03 µM and 0.15 µM for CPEU. The intra- and interassay coefficients of variation for CPEC 
and CPEU were less then 10%. The usefulness of the method was demonstrated by analyzing 
CPEC and CPEU in plasma of a patient treated with CPEC. HPLC with electrospray ionization 
tandem mass spectrometry allowed rapid and sensitive determination of CPEC and CPEU levels 
in plasma.
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INTRODUCTION
The experimental drug cyclopentenyl cytosine (CPEC) is a pyrimidine analogue of cytidine 
(figure 1). The active metabolite CPEC-triphosphate (CPEC-TP) is formed after transmembrane 
transport and the successive phosphorylation by the enzymes uridine-cytidine kinase, nucleoside 
monophosphate kinase and nucleoside diphosphate kinase. CPEC-TP inhibits cytidine triphosphate 
synthetase (CTP synthetase) which is known to catalyse the formation of cytidine triphosphate 
(CTP) from uridine triphosphate (UTP). Inhibition of CTP synthetase leads to diminished RNA 
and DNA synthesis and accumulation of cells in the S-phase of the cell cycle. Although CTP can 
also be synthesized by the salvage of cytidine, it has been shown that several malignant tissues 
predominantly use the pathway involving CTP synthetase [1,2]. CPEC can be deaminated to 
its metabolite cyclopentenyl uracil (CPEU). Pharmacokinetic data from animals revealed major 
interspecies differences. In rodents and dogs renal excretion of the unchanged drug was the 
primary route of elimination whereas in primates deamination to CPEU was dominant [3,4]. 
Although deamination to CPEU accounted for a significant part of the elimination in humans, 
elimination of CPEC occurred mainly by renal excretion of the unchanged drug [5]. 
CPEC has been studied in humans in a phase I trial involving 26 adults with solid tumors [5]. 
Hematological toxicity was dose limiting, however, the most serious adverse effect was severe 
hypotension. Five patients experienced in total 6 episodes of hypotension, which resulted in the 
death of two patients. As the events occurred in the higher dose groups, a dose-effect relationship 
was suggested. Animal studies gave no further indication of the underlying mechanism of this 
adverse effect [6]. Currently, we are initiating phase I/II trials with low dose CPEC in adult and 
pediatric patients with refractory hematological malignancies (acute myeloid leukemia, acute 
lymphoid leukemia and myelodysplastic disorders) under strict cardiac monitoring. 
In the previous phase I trial, CPEC was measured in serum samples using a HPLC method with 
UV detection [7]. However, this method had a detection limit of 0.1 µM for CPEC, and was 
expected not to be sensitive enough when using low dosage regimens. Moreover, the method was 
laborious requiring ultra filtration and subsequent solid phase extraction of the plasma before it 
could be subjected to HPLC analysis.
Therefore, we have developed a rapid, specific and more sensitive method, using 




Chemical structure of CPEC, CPEU, 5-OH-Me-Uracil (+4) (internal standard for CPEC)  
and ribose-1-13C-Cytidine (internal standard for CPEU)
MATERIALS AND METHODS
Chemicals
CPEC (NSC375575) and CPEU (NSC375574) were kindly donated by the Drug Synthesis and 
Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment of the 
National Cancer Institute (NCI, Bethesda, Maryland, USA). The internal standards 4,5-13C2-
5',5'-D2-5-Hydroxymethyluracil (5-OH-Me-Uracil(+4)) and ribose-1-
13C-Cytidine (Cytidine(+1)) 
were obtained from Cambridge Isotope Laboratories (Andover, Massachusetts, USA). Methanol, 
acetic acid and ammonia were obtained from Merck (Amsterdam, The Netherlands) and were of 
analytical or HPLC grade. Demineralised water from a Milli Q water purification system (Millipore, 
Amsterdam, The Netherlands) was used for preparation of stock solutions. Pooled plasma (free 
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Sample preparation
INTERNAL STANDARD 
Stock solutions of Cytidine(+1), (99% pure, internal standard for CPEU) and 5-OH-Me-Uracil(+4), 
(99% pure, internal standard for CPEC) were prepared in demineralised water. A 1 mM solution 
of both stable isotopes was used as internal standard. 
SAMPLES PREPARATION
Stock solutions of CPEC and CPEU consisted of adequately weighed quantities of CPEC and CPEU 
dissolved in purified water to obtain concentrations of 4.07 mM CPEC and 1.89 mM CPEU. These 
stock solutions were combined and further diluted in purified water to obtain working solutions 
of 400 µM CPEC and CPEU. The working solutions were used to spike the plasma in appropriate 
concentrations. All solutions were stored at -20ºC. For calibration and validation, concentration 
series of CPEC and CPEU in pooled plasma (0.03 – 10 µM) were prepared. 
A volume of 20 µl internal standard was added to 200 µl plasma. Proteins were precipitated by 
adding 10 µl 11.6 M HClO4 followed by centrifugation (5 minutes 10.000 x g). Subsequently 
150 µl of the supernatant was neutralized with 5 µl 5 M K2CO3. After 10 minutes the samples 
were centrifuged in a microcentrifuge (5 minutes 10.000 x g) and an aliquot of 100 µl of the 
supernatant was injected in the HPLC-MS/MS. 
HPLC-electrospray ionization ms/ms
Separation of the components in the samples was performed on a Phenomenex Aqua C18 analytical 
column (250 x 4.6 mm) (Phenomenex, Torrance, USA). Solvent A consisted of 0.05 M acetic acid 
in water (pH set at 4.70 with 25% ammonia) and solvent B of methanol. Elution was performed by 
use of a gradient, at a flow rate of 1 ml/min, as follows: 0-6 min, 100% solvent A to 30% solvent 
B; 6-6.1 min, 30% solvent B to 80% solvent B; 6.1-9.0 min, 80% solvent B; 9.0-9.1 min, 80% 
solvent B to 100% solvent A; 9.1-15 min 100% solvent A. A splitter between the HPLC column 
and the mass spectrometer was used to introduce the eluate between 6.0 and 9.0 minutes at a 
flow of 50 µl/min into the mass spectrometer. Samples were analyzed on a Waters Micromass 
Quattro II tandem mass spectrometer (Micromass, Manchester, UK) in the positive ion mode using 
electrospray ionization (ESI). Nitrogen was used as nebulizing gas and Argon as collision gas 
(collision cell pressure 2.5*10-3 mBar). The source temperature was set at 80ºC and the capillary 
voltage at 3.5kV. Detection took place by multiple reaction monitoring (MRM) with a dwell time of 
0.1 second per channel. The following transitions and settings were used: CPEC m/z 240>112 
(cone voltage 35V); 5-OH-Me-Ura(+4): 147>86 (cone voltage 27V); CPEU 241>113 (cone 




Linearity of CPEC and CPEU was tested by injecting calibration mixtures with different 
concentrations (10, 8, 6, 2, 0.5, 0.05 and 0.03 µM). The calibration curves were obtained 
from a least-squares regression for the analyte/IS peak-area ratio versus the concentration of the 
analyte in the calibration mixture. The correlation coefficients of the calibration curves for CPEC 
and CPEU were required to be ≥ 0.990. The detection limit was established by injection of the 
calibration samples and defined as a signal to noise ratio of 3. 
Intra-assay variation (intra-day precision) and the accuracy of the method was established by 
measuring plasma enriched with CPEC and CPEU at low (0.1 µM for CPEC and 0.5 µM for 
CPEU), medium (1µM) and high (4µM) concentrations (10 samples of each concentration in 
a single run). The inter-assay variation (inter-day precision) and accuracy was established by 
measuring the low, medium and high concentrations and the calibration line on 10 different days. 
The concentration of each sample was calculated using the calibration curves. The coefficients of 
variation were considered acceptable in case they were below 10%. Accuracy was expressed as 
[(overall mean concentration/nominal concentration) × 100%], and should be within the range 
from 85 to 115%. Three samples with 0.1 µM CPEC or 1 µM CPEU were analyzed at different 
time points after storage at -20ºC (0, 1 and 2 months).
The influence of the matrix was tested by determination of the recovery of CPEC and CPEU in 
plasma samples of 10 different patients spiked with medium and low concentrations of CPEC 
and CPEU. 
Suitability of the method was tested by analyzing plasma samples that were obtained at different 
time points from a patient treated with CPEC in a phase I/II trial (approved by the Medical Ethical 
Committee of the Academic Medical Center) at our institute. In addition plasma from a mouse that 
was treated with CPEC for an in vivo study (approved by the Ethical Animal Research Committee 
of the Leiden University Medical Center) was also analyzed. 
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RESULTS
The calibration curve for CPEC was best described by a weighted (1/x) quadratic curve (R2 = 
0.997, SD = 0.002, n = 10) and not by a linear curve as non-linear responses at the higher 
points of the validation curve were observed. The calibration curve for CPEU was linear in the 
concentration range tested (r2 = 0.997, SD = 0.004, n = 10). The detection limit (defined as a 
signal-to-noise ratio of 3) for CPEC proved to be 0.03 µM and for CPEU 0.12 µM. As the detection 
limit of CPEU was below the lowest validation point, we analyzed a spiked plasma sample with a 
concentration of 0.15 µM (n=3) and found an accuracy of 90%. Therefore the detection limit of 
CPEU was set at 0.15 µM. After storage at -20ºC we found an accuracy of 92% (mean 0.09, SD 
0.006) for CPEC and 103% for CPEU (mean 1.03 SD 0.06).
Representative chromatograms of the analysis of a plasma sample spiked with CPEC (0.1 µM) 
and CPEU (0.5µM) are shown in figure 2. 
The intra- and inter-assay variations and accuracy for the different concentrations analyzed are 
represented in tables 1 (CPEC) and 2 (CPEU). The coefficients of variation (CV) were all below 
10%. The recovery of CPEC and CPEU in the different patient samples is presented in table 3.
Table 1 Intra- and inter-assay variation and accuracy for CPEC 
Intra-assay Inter-assay 
CV, % Mean (SD) Accuracy (%) CV, % Mean (SD) Accuracy (%)
0.1 µM 7.5 0.1 (0.007) 92 6.2 0.1 (0.009) 107
1 µM 5.9 1.0 (0.06) 103 5.08 1.1 (0.05) 109
4 µM 1.3 4.1 (0.05) 103 6.6 3.9 (0.3) 98
Table 2 Intra- and inter-assay variation and accuracy for CPEU
Intra-assay Inter-assay 
CV, % Mean (SD) Accuracy (%) CV, % Mean (SD) Accuracy (%)
0.5 µM 3.9 0.5 (0.02) 97 3.7 0.5 (0.02) 102
1 µM 4.4 1.0 (0.04) 97 5 1.1 (0.05) 106
4 µM 4.1 3.7 (0.2) 93 8.5 4.0 (0.3) 100
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Table 3 Recovery in 10 different plasma samples
CPEC CPEU
CV, % Recovery, % (SD) CV, % Recovery % (SD)
0.1 µM 10.1 100.0 (1.0) nd nd
1 µM 10.0 99.0 (1.0) 4.5 95.0 (4.2)
nd = not determined
In plasma samples from a patient treated with low dose CPEC (1 mg/m2/h for 24 hours), CPEU 
could be detected at the end of the infusion period and CPEC could be detected up to 48 hours 
after the end of the infusion (figure 3). When analyzing the plasma of a mouse treated with CPEC 
(5 mg/kg on 3 consecutive days) a concentration of 0.24 µM for CPEC was found, whereas no 
CPEU could be detected in the plasma of a control mouse that was treated with saline.
Figure 2
HPLC-ESI MS/MS chromatograms of CPEC and internal standard cytidine(+1) 
and CPEU and internal standard 5-OH-Me-Uracil(+4).
Cytidine(+1)
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DISCUSSION 
The first Phase I study with CPEC performed by Politi et al, showed that plasma levels of CPEC 
were in the low micromolar range. That study described two rapid phases of elimination after 
a bolus injection (24 mg/m2) in two patients. A late phase of elimination was also suggested, 
however, it was not possible to describe this phase of the pharmacokinetics profile as plasma 
concentrations 24 h after the end of the infusion were below the limit of quantitation of the used 
HPLC-UV method. Plasma levels in that study increased linearly with CPEC dose. The phase I 
study was terminated because of severe cardiovascular adverse events in the patients receiving 
more than 2.5 mg/m2 CPEC [5]. Due to these adverse effects, new trials with CPEC will apply 
lower dosages (0.5-1.5 mg/m2/h for 24 hours) and remain under 2.5 mg/m2/h. Monitoring of 
the plasma levels will be necessary to detect possible toxic plasma levels and to further explore 
CPEC pharmacokinetics. With lower dosages of CPEC, plasma levels are expected to be lower 
than 0.1 µM shortly after the end of the infusion. In order to be able to measure these low 
plasma CPEC concentrations, the use of a sensitive method allowing the quantification of CPEC 
at concentrations below 0.1 µM CPEC is necessary. Therefore, we developed a new HPLC-ESI 
MS/MS method, which proved to have the required sensitivity. With the method described and our 
instrumentation, CPEC can be detected at concentrations as low as 0.03 µM and CPEU at 0.15 
µM. An additional advantage is the high specificity of the method making extraction unnecessary 
and offering an easy and rapid workup of the plasma samples. We found no signs of degradation 
of CPEC and CPEU upon storage. Earlier experiments also showed no degradation of CPEC for 
several years in aqueous solutions [8] and CPEC was found to be enzymatically and hydrolytically 
stable in plasma [7]. 
Internal standards for CPEC and CPEU were added to the plasma samples to compensate for 
losses during sample preparation and sensitivity loss due to quenching of the signal in the mass 
spectrometer. Cytidine(+1) and 5-OH-ME-Uracil(+4) were chosen as no isotopically labelled 
CPEC and CPEU were available.
In the phase I study the maximum concentration of CPEC after a bolus injection of 24 mg was 
approximately 10 µM. This was also the maximum concentration in our calibration line. Steady 
state plasma concentrations in the study increased from 0.4 to 3.1 µM at dose levels of 1 to 
5.9 mg/m2/h. As in the phase I/II study in our institute dose levels of 0.5-1.5 mg/m2/h CPEC 
would be applied, we expected lower steady state plasma concentrations and therefore the lowest 
concentration for testing the intra- and inter-assay variation was 0.1 µM. The samples of the 
patient treated with low dose CPEC confirmed that plasma levels remain in the lower range as a 
maximum concentration of 0.58 µM of CPEC was detected. CPEU levels were lower than CPEC 
levels and at several time points the concentrations were below the detection limit of 0.15 µM. 
However, after the end of the infusion a maximum concentration of 0.16 µM was found. The 
low CPEU concentrations are in line with previous data from the phase I study indicating that 
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deamination of CPEC is not the primary route of excretion in humans [5]. CPEU has almost no 
cytotoxic effects [9,10]. Moreover, cardiotoxicity in the phase I study was not associated with 
CPEU concentrations. Therefore, the inability to quantify very low CPEU concentrations will not 
hamper the use of our method in clinical practice.
As demonstrated by the plasma levels of CPEC of the mouse, the method is also suitable for 
use in animal studies. Moreover, analysis of the plasma of an untreated mouse, suggested no 
interference of the difference in matrix with the method. 
In conclusion, with the described HPLC-ESI MS/MS method we show that plasma 
concentrations of CPEC and CPEU can be measured at low concentrations with a simple and 
rapid preparation of the samples. The method can be used for monitoring plasma levels of 
patients treated with CPEC.
Figure 3
CPEC and CPEU plasma concentrations of a patient treated with CPEC (1 mg/m2/h for 24 hours). 
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The experimental cytotoxic drug cyclopentenyl cytosine (CPEC) is a non-competitive inhibitor 
of the enzyme cytidine triphosphate (CTP) synthethase. We evaluated the in vitro and in vivo 
antitumor activity of CPEC on human ALL cell lines. CPEC displayed anti-leukemic activity with 
IC50 (after 3 days of incubation) ranging from 6 to 15 nM. Subsequently the in vivo activity of 
CPEC against primary human ALL was evaluated in a xenogeneic model of human ALL using 
NOD/scid mice inoculated with primary human ALL cells. In the model, only a marginal anti-
leukemic activity was observed at 1.5 mg/kg (5 days per week) and 5 mg/kg (2 days per week), 
however, this activity was associated with severe systemic toxicity. The observed toxicity was not 
specific for the NOD/scid model, as toxicity at comparable treatment intensity was also observed 
in Balb/c mice. In conclusion, although CPEC showed antitumor activity against human ALL cells 
in vitro, its activity in the in vivo human leukemia model was only marginal and accompanied by 
severe toxicity. 
 
Keywords: cyclopentenyl cytosine, CPEC, NOD/scid, leukemia, ALL
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Limited anti-tumor-effect associated with toxicity of the experimental cytotoxic drug 
cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia
INTRODUCTION
Acute lymphoblastic leukemia (ALL) generally has a poor prognosis in adults, with an overall 
leukemia-free survival of 30 to 40%. Current therapy strategies include chemotherapy and 
allogenic stem cell transplantation [1]. As prognosis decreases after the first relapse, agents 
improving first line therapy are still warranted.
In leukemic cells of adults with acute lymphoblastic leukemia (ALL), CTP (cytidine triphosphate) 
synthetase activity was found increased as compared to nonmalignant cells [2,3]. High enzyme 
activity has also been found in lymphoblasts of pediatric patients with ALL and cells of pediatric 
patients suffering from acute myeloid leukemia (AML) [4,5]. These findings suggest that CTP 
synthetase might be an attractive target enzyme for inhibition. Moreover, it has been shown that 
some malignant tissues synthesize CTP predominantly via the uridine pathway and thus via CTP 
synthetase [2].
The experimental cytotoxic drug cyclopentenyl cytosine (CPEC), is a non-competitive inhibitor 
of the enzyme CTP synthetase. CPEC is a pyrimidine analogue of cytidine in which the furan 
ring of the ribose sugar has been replaced by a carbocyclic cyclopentenyl moiety [6]. CPEC is 
activated by intracellular phosphorylation ultimately forming its 5’-triphosphate analogue (CPEC-
TP) by subsequently uridine-cytidine kinase, nucleoside monophosphate kinase and nucleoside 
diphosphate kinase [7]. CTP-synthetase catalyzes the conversion of uridine triphosphate (UTP) 
into cytidine triphosphate (CTP), which is one of the only two cellular pathways for synthesizing 
CTP. CTP is a precursor for RNA, DNA and phospholipids.
CPEC has shown to have activity in human mammary, colon carcinoma and melanoma xenograft 
models [6,8]. In humans, CPEC has been studied in a single phase I clinical trial in adults with 
a variety of solid tumors. Twenty six patients suffering from predominantly colorectal cancer were 
treated every 3 weeks with increasing doses of CPEC. Treatment was associated with dose-
dependent and dose-limiting decreases in granulocyte and platelet counts. Non dose-limiting 
nausea, vomiting, mucositis and diarrhea were also reported. The most severe toxicity observed 
was cardiovascular in the form of hypotension. From the 26 patients treated with CPEC, 5 patients 
experienced a hypotensive episode (dose range: 3-4.7 mg/m2/h for 24 h) which was in two cases 
fatal. Toxicity seemed to be dose-related as no hypotension was seen in patients receiving doses 
equal or below 2.5 mg/m2/h [9]. However, these cardiotoxic effects could not be reproduced in 
animal experiments and it remains unclear whether or not the observed hypotension was a true 
cardiotoxic side effect [10].
In vitro experiments on leukemic cell lines showed reduction of RNA- and DNA-synthesis and 
growth inhibiting effects of CPEC [7,11,12,13]. Moreover, CPEC also seemed to increase the 
phosphorylation of the cytostatic drug arabinofuranosyl cytosine (AraC) in a T-lymphoblastic 
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(MOLT-3) and a myeloid (HL-60) leukemic cell line, enhancing the cytotoxicity of AraC [13]. In 
vivo anti-leukemic activity of CPEC was demonstrated in mice inoculated with murine leukemias 
by Moyer et al [12]. 
Considering the results of the various in vitro and in vivo experiments with lymphocytic and 
myeloid leukemia, and the hematotoxic side effects in humans with solid tumors, CPEC might 
have potential in the treatment of ALL. However, the in vivo experiments providing this evidence 
were carried out in mice inoculated with murine leukemic cells from leukemia-derived cell lines 
[12] whereas no data are available with human leukemic cells. 
We therefore studied the antitumor effect of CPEC on human acute lymphoblastic leukemia cell 
lines in vitro, as well as on corresponding human primary acute lymphoblastic leukemia cells 
in a xenogeneic in vivo model. Although CPEC exerted activity on human leukemic cell lines, 
CPEC displayed no detectable activity at tolerated (i.e. non-lethal) doses, suggesting a minimal 
therapeutic window in ALL. 
METHODS
Leukemic cells 
We established a number of continuously proliferating ALL cell lines. These cell lines were 
generated from primary cells by culturing these cells in a serum-free medium that was previously 
developed [14]. The emerging cell lines displayed similar phenotype as compared to the primary 
cells. Karyotype analysis revealed similarity with primary cells although additional aberrations 
were observed in some, but not all, cell lines. The leukemic cells were obtained by leukapheresis 
from 5 patients with ALL after informed consent. Patient and cell line characteristics are presented 
in Table 1.
The serum-free medium consisted of IMDM (BioWhittaker, Verviers, Belgium), supplemented 
with 3mM L-glutamine (BioWhittaker), antibiotics, 0.4% human serum albumin (HSA) (wt/vol) 
(Sanquin, Amsterdam, The Netherlands), 20 µg/ml cholesterol (Sigma-Aldrich, Zwijndrecht, The 
Netherlands), 2 µg/ml transferrin (Serva, Heidelberg, Germany), 5x10-5 M β-mercaptoethanol 
(Sigma-Aldrich), and 10 µg/ml insulin (Sigma-Aldrich).
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Table 1 Patient and cell line characteristics
Patient Diagnosis Karyotype of primary cells Cell line Karyotype of cell line**



































*CML in lymphoid blast crisis. **Additional abberations as compared to the primary cells are underlined.
In vitro proliferation assay
The effect of CPEC (NCI, Maryland, USA) and cytarabine (AraC) (Pfizer, Capelle a/d IJssel, The 
Netherlands) on proliferation of leukemic cell lines was tested by [3H]thymidine incorporation 
assay. Leukemic cell lines were cultured in the absence or presence of the agents in 96-well tissue 
culture plates (Corning Costar, Schiphol-Rijk, The Netherlands) at 4 x 104 cells/well in serum-
free medium). After 72 hours of incubation, 1 µCi [3H]thymidine (Amersham, Roosendaal, The 
Netherlands) was added to each well. After 18 h of further culture [3H]thymidine incorporation was 
measured as described earlier [15]. By using the isobologram method [16] we analyzed whether 
the combination of CPEC and AraC was synergistic, additive or antagonistic. We determined the 
concentration combinations that caused 50% survival for the different cell lines. For each pair of 
drug concentrations producing 50% survival (IC50), the combination index (CI, based on Loewe 
additivity [16, 17] was calculated as follows: CI = (CPEC concentration/IC50 CPEC) + (AraC 
concentration/IC50 AraC). IC50 CPEC and AraC in this formula represent the concentrations of 
the individual drugs that would result in 50% survival. 
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In vivo NOD/scid mouse leukemia model
Female NOD/scid mice, aged 5-6 weeks (Charles River, les Oncins, France) were housed in 
sterile cages supplied with sterile filtered air and were supplied with sterile food and sterile water 
containing ciprofloxacin. Mice were engrafted with primary human leukemic cells by injecting 
106 leukemic cells intravenously in a lateral tail vein. Engraftment and progression of leukemia 
was monitored twice a week by flowcytometric analysis of peripheral blood samples of individual 
animals as described before [18]. Briefly, blood samples were taken from a lateral tail vein by 
using capillary blood collection tubes (Sarstedt, Nümbrecht, Germany). Total nucleated cell 
counts (NCC) were determined on a Sysmex F 820 automated cell counter (Sysmex Corparation, 
Kobe, Japan). After lysis of red blood cells, murine leukocytes and human ALL cells were stained 
using PE-conjugated anti-murine CD45 (Ly5; Pharmingen, San Diego, CA) and FITC-conjugated 
anti-human CD45 (Becton Dickinson, San Jose, CA) respectively, allowing determination of the 
percentage of murine and human cells (%Hu). Samples were analyzed on a Becton Dickinson 
FACScan flow cytometer. Leukemic cell counts (LCC, 106/ml) were calculated as LCC = NCC 
(106/ml) x %Hu.
Treatment was performed by administrating CPEC (in 200 µl normal saline) or normal saline 
(control group) intravenously as a bolus injection in the tail vein. Animals were further monitored 
for response or tumor progression. Toxicity was evaluated by determining weight loss, hemaglobin 
(Hb) and visual aspects (breathing, activity, shaking). At the end of the experiment, or after 
observing severe toxicity (>20% weight loss), animals were euthanized by CO2 inhalation. Blood, 
bone marrow and spleen were tested for leukemic cells. Heart, spleen, liver and kidney were 
further processed for histological evaluation. For this purpose paraplast embedded organs were 
mounted on slides and stained with haematoxylin-azophloxin.
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RESULTS
In vitro experiments
To evaluate the activity of CPEC on human leukemic cells, we incubated five different cell lines 
with CPEC (1-1000 nM) for 72 hours. The mean IC50 of CPEC was 12 nM (range 6-15 nM). 
Total cell death was observed at 50 nM and higher. By comparison, the IC50 of AraC was 
2-4 nM. (Fig. 1). 
As earlier studies reported a possible synergistic effect of Ara-C and CPEC, we also studied 
anti-leukemic activity of combinations of CPEC and AraC. In figure 2 the isobologram of the co-
incubation of CPEC and AraC (concentration CPEC 0-63 nM, AraC 0-32 nM) is presented. Most 
of our data are slightly above the diagonal that defines Loewes additivity. We also calculated the 
average CI from all the concentration combinations giving 50% survival. The average CI was 
1.09 (SD 0.13) and as defined by Chou, CI values between 0.90 and 1.10 may be considered 
as nearly additive [19].
Figure 1 Activity of CPEC on proliferation of ALL cells
To study the in vitro activity of CPEC and AraC, five different leukemic cell lines (derived from primary leukemic cells from 
5 patients with ALL) were exposed to serial dilutions of CPEC and AraC (1-1000 nM). A thymidine incorporation assay was 
performed after 3 days of incubation. The results shown in the figure are representative of three separate experiments. The 
IC50 of AraC was observed at 0.002-0.004 µM, IC50 of CPEC at 0.006-0.015 µM. 




























Figure 2 Absence of synergistic activity of coincubation of CPEC and Ara-C in vitro
Isobologram showing absence of synergistic activity of co-incubation of CPEC and AraC in vitro
To study a possible synergistic effect of CPEC and AraC, 4 leukemic cell lines (derived from primary leukemic cells from 
patients with ALL) were exposed to serial dilutions of CPEC and AraC. The thymidine incorporation assay was performed after 
3 days of coincubation. Data points represent the drug combinations leading to 50% survival. The diagonal represents Loewe 
additivity. On the axis percentages of the IC50 concentrations of the drugs are plotted. The isobologram indicates a nearly 
additive and no synergistic effect.
In vivo experiments
The five ALL cell lines displayed similar sensitivity to CPEC in vitro. As the in vitro experiments did 
not show a superior effect of CPEC and AraC co-incubation over CPEC alone, we chose to study 
CPEC mono-therapy in vivo. Primary leukemic cells from patients MHX and COA, from which the 
HP and CM cell lines were previously generated, were selected for evaluation in the animal model. 
These patients were selected in order to include both a Philadelphia (Ph) positive (COA) as well as 
a Ph negative sample (MHX) in the in vivo studies. Mice inoculated with cells from patient MHX 
first showed quantifiable leukemic cell counts (LCC) 84 days after inoculation. Mice inoculated 
with cells from patient COA first showed quantifiable LCC 17 days after inoculation. 
In the phase I study CPEC was tested in a dose range from 0.7 – 4 mg/kg/day as a 24 h infusion 
every three weeks [9]. As in vivo studies on murine leukemia demonstrated activity of CPEC in 
a more frequent dose schedule [12], we started with administration of CPEC on 2 days/week (2 
consecutive days followed by 5 days of rest). Three dosages were tested: 0, 0.5 and 5 mg/kg (3 
mice per group). Only the highest dose was associated with marginal activity, however, this was 
accompanied by severe toxicity. We therefore tested whether a more intense schedule with a lower 
maximum dose would result in more effect with less toxicity. We administrated respectively 0, 0.5 
and 1.5 mg/kg for 5 times a week (4 mice per group). Still neither effect nor toxicity was seen in 
the lower dose ranges. A marginal effect was associated with 1.5 mg/kg, however, again severe 
toxicity, expressed by more than 20% decrease in weight or Hb, was observed. The logLCC counts 
for the two dose schedules tested are represented in figure 3.
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Figure 3a logLCC counts for 
MHX ALL cells in NOD/scid 
mice
Figure 3b logLCC counts for 
COA ALL cells in NOD/scid 
mice
Figure 3 Marginal activity accompanied by severe toxicity of CPEC on primary ALL cells in NOD/scid mice
In figure 3a data from mice inoculated with MHX primary leukemic cells are shown.
CPEC administration was started in this group 104 days after inoculation. Mice received CPEC on two consecutive days with a 
5-day interval for a maximum of four weeks (time points of the first and last injection are indicated by the arrow). Each curve 
represents the mean logLCC counts for each group during the study.
Figure 3b represents data from mice inoculated with COA primary leukemic cells. CPEC administration was started 46 days 
after inoculation. Mice received CPEC for five days per week for a maximum of four weeks.
In both figures the highest dose group demonstrate a possible treatment effect of CPEC. However, these were the only groups 













































In animals treated with more than 1.5 mg/kg CPEC/day, analysis of blood samples revealed 
induction of pancytopenia and anemia. After 1.5 mg/kg CPEC for 5 days/week hemoglobin levels 
decreased to 5.7 mmol/l (SD 0.74) as compared to 8.6 mmol/l (SD 0.49) in control treated 
animals within 14 days after treatment start. Diarrhoea and significant weight loss (>25%) 
were observed. Hematological toxicity of CPEC was confirmed microscopically. The bone marrow 
compartment of treated animals was void of hematopoietic cells (Fig. 4). In the kidneys tubular 
necrosis, and signs of proteinuria and bleeding were observed (Fig.5). Gut toxicity of CPEC 
presented as atrophy of ilear epithelium. No signs of cardiotoxicity were found.
No toxicity was observed in the lower dosage regimens (equal or below 1.0 mg/kg CPEC, 5 days/week).
To investigate whether susceptibility to CPEC-mediated toxicity was a strain-specific trait of NOD/
scid mice, we administrated CPEC to non-leukemic Balb-c mice. Although 1.5 mg/kg (5 days/week) 
was well tolerated, daily administration of 5 mg/kg CPEC resulted in severe toxicity and death.
Figure 4 Severe aplasy in the bone marrow compartment after CPEC treatment
Details of the femur of a CPEC treated animal (revealing severe aplasy in the bone marrow) (4a), whereas no abnormalities 
were observed in the femur of an untreated animal (figure 4b). 
Figure 5 Kidney toxicity after CPEC treatment
Details of the kidney showing tubular necrosis, signs of proteinurea and bleeding after treatment with CPEC (figure 5a). In 
figure 5b details of the kidney of an untreated animal are shown.
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DISCUSSION
With this study we demonstrated that CPEC has in vitro activity on human leukemic cells. However, 
in our NOD/scid model CPEC showed no detectable activity at tolerated doses whereas at higher 
doses limited activity was associated with severe toxicity. Balb/c mice were also susceptible to 
CPEC toxicity, suggesting a minimal therapeutic window in ALL. 
CPEC has been evaluated clinically in the phase I study by Politi et al in patients with solid tumors 
[9]. In this study hematological toxicity was dose-limiting and the most severe side effect was 
cardiotoxic. The cardiotoxicity only occurred in the higher dose levels and could not be reproduced 
in animal experiments [10]. The hematological toxicity however, suggested a potential antitumor 
effect in leukemia. Various in vitro and in vivo experiments with CPEC on lymphoid and myeloid 
leukemia seemed to confirm this hypothesis [7,11,12,13]. These in vivo experiments however, 
were murine tumor-based models. Therefore, the activity of CPEC against primary human leukemia 
cells in vivo remained unclear.
In vitro, on previously established LeidenALL acute lymphoblastic leukemia cell lines, CPEC 
exerted antileukemic activity in the nanomolar range, comparable to other reports. Previously, 
Verschuur et al reported a synergistic effect between AraC and CPEC because co-incubation with 
AraC and CPEC increased cell death in a T-lymphoblastic cell line (Molt-3) as compared to either 
agent alone[20]. However, in our B-lineage ALL cell lines, we detected a nearly additive and no 
synergistic relationship between the activity of CPEC and cytarabine. Therefore, we investigated 
monotherapy with CPEC in the in vivo model for primary human ALL. 
Previous experiments in mice bearing murine lymphoid leukemia reported an antitumor effect of 
CPEC when administrating 1 mg/kg CPEC for a maximum of 9 days [12]. In these experiments 
CPEC activity was evaluated by measuring the increase in life span, giving no indication on 
the actual activity of CPEC during treatment. Moreover, since both treated and untreated mice 
died within 20 days after inoculation, no discrimination between death due to toxicity of CPEC 
or leukemic progression was made. In our tumor model, leukemic progression is continuously 
monitored, allowing the identification of the actual response during treatment [17]. Because of 
the application of this technique, leukemic progression can be excluded as a possible cause of 
death. This allows precise discrimination between activity and toxicity of therapeutic interventions. 
Moreover, the model employs a curative setting (i.e. treatment is started after confirmation of 
leukemic engraftment ), whereas in the earlier experiments treatment is applied simultaneously 
with, or very shortly after tumor inoculation.
In the present studies, CPEC at highest doses, appeared to induce a small decrease in leukemic 
progression. However, this activity was accompanied by severe anemia. There were no indications 
of preferential toxicity of leukemic cells. Histological findings confirmed hematological toxicity as 
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severe aplasy was observed in the bone marrow. No cardiotoxicity was detected upon histological 
examination. Besides hematological toxicity, renal toxicity was apparent. It remains unclear 
however, whether renal toxicity was primary and caused anemia through hematuria, or whether 
renal necrosis was secondary and caused by anemia and the resulting hypoxia. 
Non-hematological toxicity consisted of weight loss and diarrhea. Upon histological examination 
the ileum showed abnormalities that might be related to the diarrhea. Moreover, in the phase I 
trial patients experienced (non dose-limiting) grade 2 diarrhea, occurring more frequently in the 
higher dosage levels. It is conceivable that a possible hematological effect in humans will be 
associated with diarrhea as well. 
To exclude the possibility that the small therapeutic window that was observed in our in vivo studies 
was a specific artifact of the NOD/scid mice model, we also administered CPEC to non-leukemic 
Balb/c mice. Although Balb/c mice tolerated CPEC at a dose of 1.5 mg/kg/day, administration of 
5 mg/kg/day induced similar and severe toxicity (both hematological and non-hematological) as 
was observed in NOD/scid mice. Although these observations suggest that Balb-c mice may be 
slightly less sensitive to CPEC-mediated toxicity, it has to be noted that the coping ability of the 
hematopoietic system of leukemic NOD/scid mice may be impaired due to leukemic engraftment. 
Moreover, the highest dose tolerated by Balb-c mice (1.5 mg/kg 5 days/week) was not associated 
with a clear anti-leukemic activity in the NOD/scid mice.
Our in vitro results with CPEC are in line with previous studies and although in vitro less active that 
AraC, CPEC showed promising activity. The fact that we were not able to demonstrate this activity 
in vivo, might have been partly caused by CPEC induced toxicity which may have overwhelmed 
anti-leukemic activity. However, other in vivo models with solid and lymphoid tumors showed 
activity of CPEC before severe toxicity occurred [12]. It is possible that cytidine is involved in 
the low activity of CPEC in mice. In vitro results in leukemic and colorectal cells have shown 
an increase in survival after administration of cytidine to CPEC treated cells. The mechanism of 
action is supposed to involve competition for transmembrane transport and phosphorylation [7]. 
It is conceivable that high endogenous cytidine levels could protect tumor cells against CPEC. 
However, administration of cytidine has also been shown to protect against toxicity, without 
changes in activity [11]. The results of our study are not suggestive for an important role of 
cytidine, as we studied the effects of CPEC on a systemic single cell leukemic tumor and we 
experienced systemic toxicity. If high endogenous cytidine levels were responsible for the lack of 
activity in our model, this would most likely also have resulted in lower toxicity, which was not 
the case.
We conclude that, although CPEC shows antitumor activity against human ALL cells in vitro, its 
antitumor activity in the human in vivo leukemia model as a single agent is only marginal and is 
accompanied by severe toxicity. 
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Cardiotoxicity is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines 
and can lead to long term morbidity. The mechanism of anthracycline induced cardiotoxicity 
seems to involve the formation of free radicals leading to oxidative stress. This may cause 
apoptosis of cardiac cells or immunologic reactions. However, alternative mechanisms may play 
a role in anthracycline induced cardiotoxicity. Cardiac protection can be achieved by limitation of 
the cumulative dose. Furthermore, addition of the antioxidant and iron chelator dexrazoxane to 
anthracycline therapy has shown to be effective in lowering the incidence of anthracycline induced 
cardiotoxicity. Other cytotoxic drugs such as 5-fluorouracil, cyclophosphamide and the taxoids are 
associated with cardiotoxicity as well, although little is known about the possible mechanisms. 
Recently, it appeared that some novel cytotoxic drugs such as trastuzumab and cyclopentenyl 
cytosine also show cardiotoxic side effects.
Keywords: Cardiotoxicity; cytotoxic drugs; cancer; chemotherapy
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INTRODUCTION
Cardiotoxicity occurs during therapy with several cytotoxic drugs and may be the dose limiting 
factor in cancer treatment and hence tumour response. Furthermore, cardiotoxicity can also 
be responsible for long term side effects and may cause severe morbidity in surviving cancer 
patients [1], which may be relevant especially in pediatric oncology. Cardiotoxicity from cytotoxic 
treatment is known to have a high prevalence [2]. Cardiotoxicity includes a wide range of cardiac 
effects from small changes in blood pressure and arrhythmias to cardiomyopathy. In literature 
different mechanisms of chemotherapy induced cardiotoxicity are postulated including cellular 
damage due to the formation of free oxygen radicals and the induction of immunogenic reactions 
with the presence of antigen presenting cells in the heart [3]. Moreover, the influence of the 
cytotoxic agent on certain phospholipids, especially cardiolipin, may also explain the development 
of cardiotoxicity [4].
The anthracyclines, such as doxorubicin and epirubicin, are potent cytotoxic drugs but their clinical 
use is often limited by their cardiotoxic side effects. Other cytotoxic drugs that have reported 
cardiotoxicity include 5-fluorouracil, capecitabine, mitoxantrone, cisplatin, the taxoids paclitaxel 
and docetaxel and newer drugs such as the monoclonal antibody trastuzumab [5-8].
In this manuscript the different mechanisms of chemotherapy induced cardiotoxicity and attempts 
to circumvent this side effect are reviewed.
ANTHRACYCLINES
Cardiotoxicity has been extensively reviewed with the use of anthracyclines [2,5,9,10]. 
Anthracyclines have been reported to cause cardiomyopathy, congestive heart failure and ECG 
alterations (e.g. nonspecific ST-T changes, decreased QRS voltage and prolongation of QT interval). 
Both early and late onset cardiac effects are reported. Early onset effects occur within one year after 
start of the anthracycline therapy and can be acute, subacute or chronically progressive. In children, 
early onset cardiotoxicity seems to occur less frequently than late onset clinical cardiotoxicity. Late 
onset effects can occur up to 20 years after completion of anthracycline therapy [11].
Acute toxicity
Acute or subacute cardiotoxicity with anthracyclines is rare and will occur during or immediately 
following infusion, is usually transient (e.g. electrocardiographic abnormalities such as nonspecific 
ST-T changes and QT prolongation, pericarditis–myocarditis syndrome and ventricular dysfunction 




The chronic effects start with early cardiac abnormalities which can progress to overt cardiac 
disease. Chronic effects persist after discontinuation of the anthracyclines and the clinical 
symptoms may include all signs of cardiomyopathy such as electrophysiologic changes, decrease 
of left ventricular function, changes in exercise-stress capacity, and overt signs of congestive heart 
failure [2,5].
Risk factors
Cumulative dose, age, prior irradiation, concomitant administration of other chemotherapeutics 
and underlying heart disease are considered as being risk factors for anthracycline cardiotoxicity 
[12]. Of these the cumulative dose seems to be the most important factor. The usual dosage of 
doxorubicin is 60–75 mg/m2, every 3 weeks [13]. above a cumulative dose of 450–550 mg/m2 
doxorubicin, cardiomyopathy and congestive heart failure occur most frequently. However, as of 
individual variation, signs of cardiotoxicity have also been seen with cumulative dosages below 
300 mg/m2 [2,14]. The cumulative probability of doxorubicin induced cardiotoxicity was estimated 
by Von Hoff at 0.18 at a cumulative dose of 700 mg/m2, 0.07 at 550 mg/m2 and 0.03 or less at 
400 mg/m2 [13]. Recently, higher estimations were reported for the elevated cumulative doses, 
respectively, 0.48 at a cumulative dose of 700 mg/m2 and 0.26 at 550 mg/m2. An explanation 
for this difference can be the difference in determination of congestive heart failure. The risk 
estimation for the lower dosage (0.05 at 400 mg/m2) is comparable with Von Hoff’s findings 
[14]. The maximum cumulative dosage needed to obtain minimal cardiotoxicity varies among the 
different anthracyclines. With epirubicin a lower frequency of cardiotoxicity at therapeutic dosages 
is reported in comparison with doxorubicin (i.e. an incidence of 0.03 at 900 mg/m2 epirubicin is 
reported, the usual dosage is 50–90 mg/m2, every 3 weeks). A lower frequency of cardiotoxicity 
has been reported also for mitoxantrone and a new anthracycline (MEN 10755) [15–18].
Previous radiotherapy may enhance anthracycline induced cardiotoxicity. In a study, left sided 
irradiation in combination with standard adjuvant chemotherapy (doxorubicin at a cumulative dose 
of 300 mg/m2) gave 2.6% of cardiac heart failure versus 0.3% for right-sided or no irradiation [19].
Monitoring and markers of cardiotoxicity
Routine cardiac imaging studies (echocardiogram or multiple gated acquisition scans) can be 
used to identify (sub)clinical myocardial dysfunction. Endomyocardial biopsy directly measures 
the presence and extent of fibrosis due to anthracycline cardiotoxicity. However, it is limited by 
its invasiveness, need for histologic expertise and costs. There is a need for simple methods (like 
serum or plasma markers) to identify patients at risk.
79
Cardiotoxicity of cytotoxic drugs
The cardiac biomarker Troponin T is indicative for myocardiocyte damage and is currently used 
in the diagnosis and prognosis of myocardial ischemia. In children treated with anthracyclines 
elevation of Troponin T was found. These elevations were, however, well below those observed in 
patients with myocardial infarction [20].
Studies in adults have given conflicting results regarding Troponin T elevations. In one study no 
change in Troponin T could be found, whereas in another an elevated level was associated with 
a greater decrease in left ventricular ejection fraction (10% vs 2%, p=0.017) [21]. Another 
possible biochemical marker is BNP (b-natriuretic peptide). ANP (atrial natriuretic peptide) and 
BNP are hormones that are secreted by the myocytes of the heart. The plasma concentrations 
are increased in patients with asymptomatic and symptomatic left ventricular dysfunction. BNP 
seems to be a more sensitive marker of cardiac dysfunction than ANP. A few small studies 
concerning the relationship between anthracyclines, BNP and cardiotoxicity have been published. 
BNP measurement in 27 patients, treated with anthracyclines for hematological cancers, showed 
significant BNP elevations after anthracycline treatment. Due to a short follow-up and the small 
size of the group this, however, could not be related to existing cardiotoxicity [22]. Another 
study in 30 patients suggested that the natriuretic peptides cannot predict cardiotoxicity, but 
can be useful in the detection of subclinical left ventricular dysfunction [23]. Further studies are 




The most common hypothesis for the mechanism by which anthracyclines cause cardiotoxicity 
includes the formation of free radicals and superoxides [15;24–26]. this hypothesis is based 
mainly on in vitro experiments and only a few studies have been performed in humans. Several 
in vitro and in vivo models have been used to study the cardiotoxic effects of anthracyclines 
assessing a variety of endpoints. With the free radical theory the reaction starts with a one-electron 
reduction of doxorubicin to form a doxorubicin semiquinone radical by a reduced flavoenzyme 
such as NADPH-cytochrome P450 reductase. The semiquinon radical forms a complex with iron 
leading to an anthracycline-iron (Fe2+) free radical complex. This complex reduces oxygen to 
produce superoxide and to regenerate doxorubicin. The superoxide is dismutated into hydrogen 
peroxide and oxygen (fig. 1). Vasquez et al have shown that doxorubicin binds to the reductase 
domain of endothelial nitric oxide synthase. This causes an increase in superoxide and a decrease 




From the combination of superoxide, hydrogen peroxide and free iron, lipid peroxidation may be initiated.
The specific susceptibility of the cardiac cells to the oxidative stress would be due to relatively 
low levels of antioxidant enzymes in the heart [27]. Indeed studies in rat hearts suggest that 
doxorubicin is able to cause a further reduction in the a priori low levels of the antioxidant 
enzymes in rat hearts [28].
Following the oxidative stress theory, cardiotoxicity can be achieved by different mechanisms. 
Studies indicate that the myocardial damage caused by doxorubicin involves apoptosis. This 
programmed cell death process would be initiated by the formation of oxidative free radicals. 
Apoptotic cell death was indeed found in rat cardiomyocytes and bovine aortic endothelial cells 
upon exposure to doxorubicin [3,29].
Sawyer et al [30] also showed apoptosis at low concentrations (1 µM) of daunorubicin, whereas at 
higher concentrations (>10 µM) necrosis was observed. This is in agreement with the observation 
of Guchelaar et al [31] who reported that in cell lines for a variety of apoptosis-inducing anticancer 
drugs a relatively increase of induction of necrosis was observed at high drug concentrations 
whereas at lower concentrations apoptosis dominates.
Figure 1
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METABOLITE THEORY
Minotti et al suggest that cancer patients often have a spontaneous exacerbation of lipid 
peroxidation and doxorubicin probably inhibits this effect in a paradoxic manner. It is suggested 
that lipid peroxidation occurs when iron oxidizes incompletely to the ferric form. Doxorubicin and 
the formed hydrogen peroxide would inhibit cardiac lipid peroxidation by affecting the Fe(II)–
Fe(III) equilibrium of iron–oxygen complexes. This would mean that cardiac damage might involve 
parent doxorubicin or its metabolites other than the semiquinon. This hypothesis is strenghtened 
by results of a study in which the formation of the metabolite doxorubicinol was demonstrated. 
This metabolite mediates iron release and negatively affects the function of apoprotein as an iron 
regulatory protein [32,33].
INFLUENCE ON CALCIUM HOMEOSTASIS
Another possible mechanism involves the influence of anthracyclines on the calcium homeostasis. 
Before leading to apoptosis, oxidative stress can induce mitochondrial permeability transition with 
alterations in mitochondrial calcium transport. Changes in calcium transport can lead to tissue injury 
and cell killing and impaired cardiac contraction. In vitro experiments showed that doxorubicin 
treatment caused an irreversible decrease in mitochondrial calcium loading capacity [34].
Moreover, anthracyclines could stimulate the release of calcium from isolated cardiac and skeletal 
muscle sarcoplasmic reticulum vesicles [35]. This theory is strengthened by the observation of 
Rossi et al. who found a protective effect of the calcium blocking agent verapamil on doxorubicin 
induced cardiotoxicity in rats. This effect would be due to the calcium blocking capacities of 
verapamil by inhibiting the intracellular calcium overload and hence antagonizing the effect of 
doxorubicin on mitochondria [24]. However, others have demonstrated an increase in cardiotoxicity 
when doxorubicin was given in combination with verapamil and different mechanisms for this 
effect are postulated. One is based on the capacity of verapamil to inhibit the function of P-
glycoprotein and therefore may increase intracellular cytotoxic drug concentrations. This may 
be useful in overcoming resistance to chemotherapeutic drugs in cancer cells, but the concern 
is that it could also lead to toxic effects in normal such as cardiac cells. Some in vitro studies 
indeed showed increased doxorubicin accumulation in rat cardiomyocytes when incubated with 
a combination of verapamil and doxorubicin [36,37]. Akimoto et al [38,39] did not show an 
increased cellular anthracycline uptake but additive cardiotoxicity by verapamil due to its selective 
inhibition of cardiac actin gene expression, a similar effect which was demonstrated before with 
doxorubicin alone. The exact role of the altering capacities of doxorubicin on calcium regulation 
and its implications for cardiotoxicity remains to be elucidated.
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ROLE OF IMMUNE SYSTEM
Involvement of an immunogenic reaction after oxidative stress is an alternative mechanism 
of anthracycline induced cardiotoxicity. Huber [40] suggested that doxorubicin could lead to 
a damaged plasma membrane of cardiac myocytes with consequently an enhanced immune 
response. A study in hypertensive rats showed an increase in antigen presenting dendritic cells 
after treatment with doxorubicin, indicating a stimulation of expression of antigens. Pretreatment 
with dexrazoxane attenuated this increase, confirming the suggestion of the involvement of 
oxidative stress, followed by an immunogenic reaction [41].
Protection
Apart from cumulative dose limitations several attempts have been made to develop 
chemoprotectants to prevent the cardiotoxicity of anthracyclines without attenuating their anti-
tumor effect. Following the free radical hypothesis, antioxidants used as free radical scavengers 
have been tested in clinical trials but without significant success. Human studies with the 
scavengers acetylcysteine or tocopherol did not show any cardioprotective effect [42,43]. In one 
clinical study, administration of melatonin together with different chemotherapeutic regimens was 
associated with reduced overall toxicity including cardiotoxicity. This effect was thought to be 
ascribed to its antioxidant capacities [44].
DEXRAZOXANE
Considering the essential role of iron and the doxorubiciniron complex, iron chelators have been 
developed to circumvent anthracycline induced cardiotoxicity. These agents bind to intracellular 
iron and remove the iron from the anthracycline–iron complex and are applied aimed at preventing 
free radical formation [45].
Dexrazoxane (ICRF-187) was found to be the most promising agent. After being tested in animals 
[46], several clinical trials showed its capacities in reducing doxorubicin induced cardiotoxicity. 
In two multicenter double blind randomized phase III trials 15% of the patients treated with 
dexrazoxane experienced a cardiac side effect versus 31% of the patients on placebo (hazard 
ratio 2.63, p < 0.001 with log rank) [47]. Another trial reported 4% in treated versus 24% in 
nontreated patients (p= 0.02) [48]. Reported differences in cardiac side effects may be explained 
by the different criteria applied for cardiac events and different dosage schedules of doxorubicin. 
Complete protection, however, could not be achieved in most of the studies [47,48]. Moreover, it 
is not known if dexrazoxane provides any protection against late cardiovascular effects [49].
In a study in children treated with doxorubicin (38 patients, 18 control and 20 treated with 
dexrazoxane) a cardioprotective effect of dexrazoxane was found [50]. However, because of the 
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small number of clinical trials yet performed in pediatric populations there is too little evidence 
to draw definite conclusions. Indeed the American Society of Clinical Oncology concluded that 
there is insufficient evidence to recommend the use of dexrazoxane in the treatment of pediatric 
malignancies [51]. The FDA has approved dexrazoxane for use in adults if cumulative doses 
of doxorubicin exceed 300 mg/m2 [5]. Doxorubicin pharmacokinetics seems to be unaffected 
upon dexrazoxane treatment [52]. A pharmacokinetic study with epirubicin revealed an increased 
clearance of the anthracycline when dexrazoxane had been administered which theoretically 
could lead to a decreased epirubicin exposure and hence a possible difference in treatment 
efficacy of the combined treatment [53]. In a randomized clinical trial however, no statistically 
significant differences in survival and progression-free survival could be demonstrated between 
the dexrazoxane and placebo group [54].
Dexrazoxane can be administered intravenously either as a slow injection or fast infusion before 
doxorubicin is initiated. The dosage to be given is usually a 10-fold of the doxorubicin dose and 
its dose limiting toxicity appears to be leukopenia [10].
MONOHER
Another radical scavenger that has been studied is the flavonoid monoher. Monoher is able to 
protect the heart against doxorubicin toxicity without affecting its anti-tumor effect in a mouse 
model. However, because of its low potency the effective dosage needed in humans would be 
too high (500 mg/kg in mice) to make it a useful drug. Recently, a derivate of monoher, called 
frederine was developed which could provide total heart protection in mice with a 5-fold lower 
dosage as compared to monoher. Clinical trials with this drug will be undertaken [55].
LIPID LOWERING AGENTS
Lipid lowering agents also seem to be able to lower the cardiotoxic effects of anthracyclines [56]. 
When rats were concomitantly treated with doxorubicin and the lipid lowering and antioxidant 
agent probucol, an increase in the antioxidant enzymes superoxide dismutase and glutathione 
peroxidase activities and a decrease in lipid peroxidation were found. According to the oxidative 
stress theory this improvement of antioxidant state of the heart could possibly lead to a better 
myocardial structure and function [28,57]. Recently, Feleszko et al [58] showed both a potentiation 
of anti-tumor activity and a cardioprotective effect by the cholesterol lowering HMG coenzyme-A 
re- ductase inhibitor lovastatin, in mice treated with doxorubicin.
CHANGES IN FORMULATION
Another strategy to achieve reduced cardiotoxicity is the development of liposomal drug 
formulations of the anthracyclines. Liposomes are preferentially taken up by tissues enriched in 
phagocytic reticuloendothelial cells and with a sinusoidal capillary system like the liver and spleen. 
84
Chapter 6
The continuous capillaries containing tissues like skeletal and cardiac muscles will therefore hardly 
take up liposomes. Preclinical studies have indeed shown a decreased uptake of doxorubicin in 
cardiac muscle cells when a liposomal formulation was used. The constituents of the liposomes 
itself do not seem to have a negative influence on the heart or other tissues. However, there may 
exist important differences among different liposomal formulations since changes in vesicle size, 
drug-to- lipid ratio and lipid composition can have great influence on the biodistribution and 
toxicity of doxorubicin [59,60].
In a retrospective analysis of eight clinical Phase I and phase II trials the safety of more than 
500 mg/m2 pegylated liposomal doxorubicin was studied. The study was performed with a 
median follow-up of 2.7 years (range 1.2–6.0 years) after the initiation of treatment. None of the 
evaluable 41 patients experienced clinical congestive heart failure secondary to cardiomyopathy. 
The left ventricular ejection fraction (LVEF) was reduced with more than 10% in five patients; 
however, three of these had received conventional doxorubicin before treatment with liposomal 
doxorubicin. The mean change in LVEF was -2%, which was not considered clinically significant. 
This study suggests that doxorubicin induced cardiotoxicity can be reduced upon using liposomal 
formulations of the drug [61].
TAXOIDS
The taxoids paclitaxel and docetaxel are important agents in the treatment of a variety of tumors 
but have been associated with cardiotoxicity [31]. During administration of paclitaxel, whether 
or not combined with cisplatin, various cardiac disturbances are reported like brady- and 
tachyarrhythmias, atrioventricular and bundle branch blocks and cardiac ischemia. Hypotension 
is also reported, probably as a result of a hypersensitivity reaction [62]. When evaluating 
three phase I and one phase II studies performed at the John Hopkins institute it appeared 
that 5% (n = 7) of the patients showed overt cardiac disturbances as ventricular tachycardia 
and atrioventricular conduction abnormalities. Asymptomatic bradycardia occurred in 29% of 
patients receiving maximal tolerable doses (110–250 mg/m2) of paclitaxel in the phase II study. 
These disturbances, however, did not lead to clinical symptoms. The abnormalities usually started 
several hours following the initiation of paclitaxel therapy and resolved after discontinuation. This 
evident time relationship and the fact that most patients had no cardiac risk factors supports the 
assumption of causality between paclitaxel and the observed cardiac rhythm disturbances [62].
Another concern with the use of taxoids has been the development of congestive heart failure 
in patients treated with a combination of doxorubicin and taxoids [63–65]. the cardiotoxicity 
associated with taxoids seems to be mild in most cases. However, in clinical trials patients with 
prior history of cardiac disturbances were often excluded. Therefore, the rate of cardiotoxicity in 
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this group of patients is yet difficult to estimate. A study in patients with major cardiac risk factors 
revealed that paclitaxel could be safely administered as single therapy or in combination with a 
platinum agent such as cisplatin or carboplatin. Cardiac risk factors included unstable angina, 
severe coronary artery disease, congestive heart failure and atrial fibrillation [66].
Mechanism
Paclitaxel is formulated in a cremophor EL vehicle to enhance the drug solubility and it is suggested 
that the vehicle and not the cytotoxic drug itself is responsible for the cardiac disturbances. 
However, the cardiac rhythm disturbances are not reported with use of other drugs containing 
cremophor EL such as cyclosporin. The possible mechanism by which cremophor EL would cause 
cardiotoxicity is massive histamine release. Indeed, stimulation of histamine receptors in cardiac 
tissue in animal studies has resulted in conduction disturbances and arrhythmias. An alternative 
explanation for paclitaxel induced cardiotoxicity could be the induction of cardiac muscle damage 
by affecting subcellular organelles [62,67,68].
Enhanced cardiac toxicity has been found in combined therapy of paclitaxel and doxorubicin. At 
doses of doxorubicin exceeding 380 mg/m2, the toxicity increased in combination therapy compared 
to doxorubicin single therapy. A pharmacokinetic interaction appears to be responsible for this effect 
as paclitaxel has been found to decrease doxorubicin hepatic elimination and therefore lead to 
increased plasma concentrations of doxorubicin. This effect depends on the interval and sequence of 
drug administration as well as the duration of the paclitaxel infusion [69]. A similar effect has been 
shown for epirubicin. The pharmacokinetics of the active metabolite epirubicinol are changed leading 
to increased plasma concentrations, whereas epirubicin pharmacokinetics remain unchanged [70]. 
In a clinical trial, combination therapy with epirubicin doses up to 720 mg/m2 was associated with 
a relatively low cumulative risk (7.7%) of congestive heart failure but increased (to 48.7%) at a 
cumulative dose of 1080 mg/m2. The study included a group patients with at least one cardiac risk 
factor and a group without cardiac risk factors (10% and 12% cumulative risk for cardiac heart 
failure, respectively, at epirubicin doses up to 990 mg/m2 ). Cardiac risk factors included were age, 
hypertension, diabetes and prior radiotherapy to the chest wall [6].
Docetaxel shows no increase in cardiac toxicity when combined with doxorubicin. This is in 
line with the observation that a pharmacokinetic interaction with doxorubicin as described for 




In combination therapy with anthracyclines, the cumulative dose of the anthracycline remains 
an important risk factor and should be lower as compared to anthracyclines monotherapy. In 
combination therapy cumulative doxorubicin doses up to 340–380 mg/m2 are reported to be safe 
whereas in monotherapy cumulative doses up to 450–550 mg/m2 can be safely administrated 
[72,73] As in mono-therapy, epirubicin is associated with less cardiotoxicity compared to 
doxorubicin in combination therapy with paclitaxel [74]. Sequential administration of doxorubicin 
and paclitaxel does not seem to increase the risk of cardiotoxicity as compared to doxorubicin alone 
[72]. However, as shown by Gianni et al [69] this seems to depend on interval and sequence.
Taxoid associated cardiotoxicity is limited and therefore no specific agents are developed 
specifically for taxoid induced cardiotoxicity. The mechanism and clinical relevance of the cardiac 
rhythm disturbances as observed with paclitaxel therapy is not yet elucidated making it difficult 
to foresee if and what kind of protection would be rational and successful.
5-FLUOROURACIL
The antimetabolite 5-fluorouracil (5-FU) is associated with myelosuppression, diarrhoea, 
mucositis and dermatitis. Cardiotoxicity may also occur and estimates of the incidence vary from 
1% to 5% to as much as 18% [5,75,76]. Cardiotoxicity with 5-FU is usually described with 
continuous infusion and less upon bolus injection. Recently, a case report was published reporting 
acute cardiotoxicity during capecitabine treatment. Capecitabine is an orally administrated 5-FU 
prodrug and can deliver 5-FU selectively to the tumour although toxicities are reported similar to 
infused 5-FU [77].
Symptoms of 5-FU cardiotoxicity include cardiac arrhythmias, silent myocardial ischemia, angina, 
congestive heart failure and even sudden death [7,8,78,79].
Risk factors include preexisting coronary artery disease and concurrent radiotherapy. Measurements 
to protect against 5-FU induced cardiotoxicity are not available yet, although symptoms (chest 
pain, nausea, diaphoresis with ECG changes) often disappear upon discontinuation of the infusion 
[76]. Fatal events, however, have been described. After having experienced cardiac side effects, 
patients are at increased risk to have a relapse if they are reexposed to 5-FU [75].
Mechanism
Several risk factors seem to be involved in 5-FU related cardiotoxicity like age, high dose 
chemotherapy, continuous 5-FU infusion and past or concomitant radiation therapy [7].
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The pathophysiological mechanism of 5-FU related cardiotoxicity is still unclear and suggested 
mechanisms cannot be explained by the pharmacological action of 5-FU. Hypotheses postulated 
are vasospasms leading to ischemia, direct toxicity on the myocardium, activation of coagulation 
system, coronary artery thrombosis, immunoallergic phenomena and cardiotoxic impurities in 
the 5-FU formulation [75,76,80,81]. A small study in 11 men treated with 5-FU unexpectedly 
showed a decrease in blood viscosity instead of an increase. The number of patients, however, 
was too small to conclude that thrombogenecity is involved in 5-FU cardiotoxicity [8]. Kohne et al 
report two patients with 5-FU cardiotoxicity who were treated successfully with the thymidylate 
synthase inhibitor raltitrexed without evidence of cardiotoxicity. The authors suggest that as 5-FU 
also targets thymidilate synthase, its cardiotoxicity is not likely due to its interaction with this 
enzyme [82].
CYCLOPHOSPHAMIDE AND IFOSFAMIDE
Cyclophosphamide and ifosfamide are alkylating oxazaphosphorine agents that need to be 
metabolized in vivo in the liver to form the active cytotoxic agent phosphoramide mustard. High 
dose cyclophosphamide is used in transplant regimens and is associated with acute cardiotoxicity 
such as cardiac decompensation as well as fatal cardiomyopathy. Acute reversible decrease in 
systolic function has been described [10,83]. The incidence has been estimated to range from 
2% to 10% [5]. Ifosfamide cardiotoxicity is reported in only a single study [84].
Mechanism
The pathogenesis is not fully understood but an increase in free oxygen radicals seems to play a 
role in oxazaphosphorine induced cardiotoxicity. This increase would be mediated by elevated in- 
tracellular levels of the actual cytotoxic metabolite phosphoramide mustard [5].
CISPLATIN
Cisplatin is a platinum substance and used in the treatment of many tumors (i.e. testicular cancer). 
Several cases of acute myocardial infarction after cisplatin therapy are reported [85,86].
In a retrospective study 87 long term survivors of metastatic testicular cancer treated with cisplatin 
were evaluated for the occurrence of cardiovascular events. A significantly increase in cardiac 




Several factors have been suggested to be involved like vascular damage, alterations in platelet 
aggregation and hypomagnesemia [85,86,88,89]. In experiments on human platelets cisplatin 
was able to trigger platelet aggregation and/or enhance thromboxane formation by platelets. 
Activation of an arachidonic pathway in platelets by cisplatin seemed to be involved [89].
TRASTUZUMAB
Trastuzumab is a monoclonal antibody directed against the HER2 receptor protein on breast cancer 
cells and it has been used alone or in combination with other chemotherapeutic agents. Cardiac 
toxicity associated with trastuzumab seems to be similar with the congestive heart failure observed 
with anthracycline therapy. Evaluation of data of 1024 patients who received trastuzumab revealed 
that combination therapy of trastuzumab with an anthracycline and cyclophosphamide showed 
28% of reported cardiac dysfunction against 3–5% with doxorubicin monotherapy (cumulative 
dosage 400 mg/m2 ). Concomitant anthracycline therapy and age appeared to be independent 
risk factors [90]. When receiving trastuzumab as single therapy in an open label study, 7% of the 
women developed heart failure [91].
OTHER AGENTS
Cardiotoxicity has been associated incidentically with several other cytotoxic drugs such as 
cisplatin, melphalan, fludarabin, mitomycin, busulfan, mechlorethamine and dacarbazine. 
However, the lack of structured data on cardiotoxic side effects of these drugs from clinical studies 
makes it difficult to assess its importance and evidence.
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CONCLUSION
Chemotherapy with certain cytotoxic drugs is associated with severe side effects such as 
cardiotoxicity. As these side effects can be dose limiting and cause severe morbidity and even 
mortality. Knowledge about their incidence and mechanism is important.
Cardiotoxicity can occur as acute or as long term side effect. With increasing survival rates interest 
is also focussed on avoiding the late onset and chronically effects.
Anthracyclines are well known for their cardiotoxic side effects and comprehensive research 
is done to explore the mechanism of anthracycline induced cardiotoxicity. Until now the most 
accepted hypothesis is the so-called ‘free radical’ theory. However, protective measurements 
following this theory such as administration of free radical scavengers have not appeared to be 
clinically successful. The antioxidant and iron chelator dexrazoxane has been successfully applied 
to protect the heart from cardiotoxicity with high dose anthracycline therapy, although complete 
abolishment of cardiotoxicity cannot not be achieved.
Other cytotoxic drugs like 5-fluorouracil, cisplatin and cyclophosphamide are also associated with 
cardiotoxicity, but yet little is known about the possible mechanisms and methods of prevention. 
Paclitaxel enhances the cardiotoxic effects of anthracyclines by inhibiting the latters metabolism 
and therefore leading to increased anthracycline exposure.
Unfortunately, cardiotoxicity is also associated with newer drugs like trastuzumab and cyclopentenyl 
cytosine and may hamper the development of potential successful anticancer drugs [92]. Further 
research is warranted to understand the mechanism of chemotherapy induced cardiotoxicity and 
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The experimental anticancer drug cyclopentenyl cytosine (CPEC) was associated with cardiotoxicity 
in a phase I study. The aim of the present study was twofold; first we investigated whether the 
observed effects could be reproduced in in vitro and in vivo rat models. Second, we intended to 
investigate the underlying mechanism of the possible cardiotoxicity of CPEC. Effects on frequency 
and contractility were studied on the isolated atria of 18 male Wistar rats. Atria were incubated 
with 0.1 mmol/l (n=6) or 1 mmol/l (n=6) CPEC for 1.5 h and compared with control atria 
(incubation with buffer solution, n=6). The cardiac apoptosis-inducing potential was studied 
in vivo on 66 rats by 99mTc-AnnexinV scintigraphy, followed by postmortem determination of 
radioactivity in tissues, histological confirmation with the TUNEL assay (late-phase apoptosis), 
and immunohistochemical staining for cleaved caspase-3 and cytochrome C (early-phase 
apoptosis). Serum levels of the necrotic cardiomyopathy marker troponin T were also determined. 
No effect on heart frequency was found in the isolated atria after CPEC treatment. A trend towards 
a decrease of contraction force was observed. However, the differences were not statistically 
significant. 99mTc-Annexin V scintigraphy showed no increase in cardiac uptake ratio upon CPEC 
treatment in the in vivo rat model, which was confirmed by determination of radioactivity in heart 
versus blood ratios. At each section a few individual isolated late apoptotic cells (<5) could be 
identified by the TUNEL assay in the highest CPEC dose group (90 mg/kg) but not in controls or in 
rats treated with 60 mg/kg CPEC. Staining for the early apoptosis markers cleaved caspase 3 and 
cytochrome C did not reveal any significant differences between treated and control rats. Cardiac 
troponin T levels were not increased after CPEC treatment. CPEC does not affect heart frequency 
or contraction force in our cardiotoxicity models. Moreover, we did not find an indication of CPEC-
induced apoptosis in heart tissue.
Keywords: Cyclopentenyl cytosine; CPEC; 99mTc-Annexine; Rat; Cardiotoxicity; Apoptosis
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INTRODUCTION
The experimental cytotoxic drug cyclopentenyl cytosine (CPEC) is a pyrimidine analogue of cytidine 
and has been studied in a phase-I trial in 26 patients with colon carcinoma. Dose-limiting toxicity 
was hematological. However, the most severe adverse reaction was cardiovascular: six episodes 
of hypotension occurred in five patients (dose range: 3-4.7 mg/m2/h). The highest applied dose 
was 5.9 mg/m2/h; no hypotension was seen in patients receiving doses below 2.5 mg/m2/h. Two 
patients, treated with 4.7 mg/m2/h, had a fatal hypotensic episode [1]. Postmortem examination 
was performed in one patient, revealing subendocardial necrosis. Therefore, the hypotension 
seemed more likely to be caused by cardiac toxicity than by a deregulation of the vascular 
tone. These observations hampered the initiation of phase II studies with CPEC. The underlying 
mechanism of the possible cardiotoxicity of CPEC is yet unclear.
In the study of Politi et al [1], a linear relationship was observed between the administered 
dose and the steady-state plasma concentration, indicating linear pharmacokinetics. After 
transmembrane transport CPEC is phosphorylated by the enzymes uridine/cytidine kinase, 
nucleoside monophosphate-kinase (NMP-kinase), and nucleoside diphosphate-kinase (NDP-
kinase) to form CPEC-triphosphate (CPEC-TP), the major metabolite. CPEC-TP is an inhibitor 
of cytidine triphosphate synthetase (CTP-synthetase); this enzyme catalyses the synthesis of the 
ribonucleotide CTP. Inhibition results in a decrease of RNA and DNA synthesis and S-phase 
accumulation. In various human and animal leukemia models, anti-tumor activity of CPEC has 
been demonstrated [2, 3]. Despite its promising anti-tumor effects in preclinical investigations, 
the unexpected and unpredictable toxicity limited the drug’s further development. However, if 
more information about the mechanism of the cardiotoxicity can be obtained, it may well appear 
that this serious side-effect can be circumvented or that the patients at risk can be selected before 
drug administration.
Cardiotoxicity is a well-known adverse effect of some cytotoxic drugs and varies from small 
changes in blood pressure and arrhythmias to cardiomyopathy [4]. Cardiotoxicity of anthracyclines 
is the best studied, and different mechanisms have been postulated, including cell damage as a 
consequence of the formation of free oxygen radicals, DNA damage as a result of disturbed DNA 
repair, and the induction of immune reactions with the presence of antigen presenting cells in the 
heart [5]. Moreover, the cytotoxic drugs may induce apoptosis more or less specifically in cardiac 
cells. Indeed, chemotherapeutics could possibly not only induce apoptosis in fast-dividing tumor 
cells, as is currently considered to be the main mechanism of action of this class of drugs [6], but 
also in healthy tissues like the heart. This hypothesis is strengthened by the observation of dose-
dependent induction of apoptosis in cardiomyocytes by doxorubicine in a rat cardiotoxicity model 
[5]. CPEC has also been associated with apoptosis. Verschuur et al [7] demonstrated apoptotic 
cell death in a T-lymphoblastic cell-line upon CPEC exposure.
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In an early phase of apoptosis the cell membrane phospholipid phosphatidylserine (PS), which is 
normally confined to the inner leaflet of the membrane, is rapidly exposed on the cell’s outer surface. 
Annexin V is a human protein (36 kDa) with high in vivo and in vitro affnity for PS and can be 
used as a marker for detection of apoptotic cells [8]. By labelling annexin V with 99mTechnetium 
(99mTc), apoptotic cell death can be imaged in vivo [9, 10]. Doxorubicin-induced apoptosis 
in the heart of rats has been imaged with 99mTc-Annexin V [11]. From preclinical studies it 
appears that CPEC has promising anti-leukemic potential and we have initiated a phase-II trial in 
adults with ALL and AML and a phase I/II study in pediatric patients with ALL and AML. In the 
phase-II trial, the CPEC doses remain below the doses at which cardiotoxic effects in the 
phase I trial were observed, and CPEC serum levels are monitored. Moreover, patients will be 
cardiovascularly monitored. However, it is necessary to learn more about the clinical toxicity, and 
in particular the possible cardiotoxicity, associated with the use of CPEC.
The objectives of the present study were twofold. First, we intended to establish the cardiotoxic 
adverse effect of CPEC in specific pharmacological and toxicological cardiac models to confirm 
or rebut the observation of drug-induced cardiotoxicity in the above mentioned phase I trial. The 
second aim was to investigate the underlying mechanism of the possible cardiotoxicity of CPEC. 
The emphasis was put on cardiac effects, a possible influence of CPEC on vascular tone was not 
investigated in this study.
Because the observed hypotension might have been caused by a decrease in contraction force or 
heart rate we studied acute effects of CPEC on these in isolated rat atria. The cardiac apoptosis-




CPEC was kindly provided by the Drug Synthesis and Chemistry Branch, Developmental Therapeutics 
Program, Division of Cancer Treatment of the National Cancer Institute, Bethesda, MD, USA. The 
raw material was analysed and processed to obtain a sterile injectable solution of 4.5 mg/ml in 
water. The analytical kit for analysis of troponin T, a marker of myocardial damage, was donated 
by Roche Diagnostics (Mannheim, Germany). The terminal transferase-mediated DNA nick end 
labelling (TUNEL) assay was obtained from Roche Diagnostics (Mannheim, Germany), and 
cleaved caspase 3 polyclonal antibody from Cell Signalling Technology. Cytochrome C polyclonal 
antibody was donated by Dr Reutelingsperger (Academic Hospital, Maastricht, The Netherlands) 
and a smooth muscle actin (a-SMA) monoclonal antibody was obtained from Sigma (IMMH-2, 
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Sigma, St Louis, USA). Paraplast for embedding the hearts was obtained from Tyco Healthcare 
(The Netherlands). HYNIC-annexin V conjugate was kindly provided by North American Scientific, 
Theseus Imaging Division, Boston, MA, USA. All other chemicals used were of analytical grade.
Animals
Male Wistar rats (200-250 g) were obtained from Harlan (Zeist, The Netherlands).
Effect on frequency and contractility
The effect of CPEC on the cardiac contractility and frequency was studied in isolated rat atria. 
Eighteen male Wistar rats were killed by stunning and decapitation. The hearts were removed 
quickly and placed in a Tyrode’s solution of composition (mmol/l): NaCl 119; KCl 4.5; MgCl2 0.5; 
CaCl2 2.5; glucose 11; Tris 30 at pH 7.5 at room temperature, and the medium was bubbled 
with 100% oxygen. The isolated atria were suspended in water-jacketed organ baths (kept at 
37°C and gassed with 100% oxygen) filled with 5 ml Tyrode’s solution (pH adjusted to 7.5 at 
37°C) and connected with a silk thread to an isometric force transducer. The left atria were paced 
with a field stimulator (Hugo Sachs Electronic, Germany) at a frequency of 3 Hz, whereas the 
right atria were allowed to beat spontaneously. The isometric force of contraction was recorded 
on a Power Lab/8s data-acquisition system (ADInstruments, Australia). The resting tension was 
adjusted to 5 mN and the atria were allowed to equilibrate for at least 45 min. At 30-min intervals 
the medium was changed to fresh Tyrode’s buffer. After equilibration, CPEC was added to the 
buffer to obtain a final concentration of 1 mmol/l (0.239 mg/ml) or 0.1 mmol/l (0.0239 mg/ml); 
these solutions were refreshed every 30 min. After 1.5 h, atria were taken out of the organ bath 
and put on ice.
In order to study whether CPEC was phosphorylated to its active metabolite and exerted its 
biological activity in this in vitro model, we determined nucleotide and CPEC-TP concentrations 
in the atria (n=8). A nucleotide extraction was performed immediately after the atria were taken 
out of the organ bath, by sonicating 2x2x2 mm3 atria samples in 300 µl 0.4 mol/l perchloric 
acid. After 10-min incubation on ice, the samples were centrifuged (5 min, 4°C, 11,000g), 
and neutralized with 15 µl K2CO3. The ribonucleotide extracts obtained were kept at 20°C. The 
nucleotides were analysed by anion-exchange HPLC as described elsewhere [3].
Cardiac apoptosis induction
The effect of CPEC on the cardiac induction of apoptosis was studied in vivo in rats and confirmed 
by histology. Male Wistar rats (six dose-levels; nine rats per dose-level) were exposed to a single 
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dose of CPEC by intraperitoneal injection. The tested dosage levels were:0, 20, 40, 50, 60 and 
90 mg/kg). To study multidose toxicity, one group of three rats received two cycles of 90 mg/kg 
on days 0 and 7. To avoid potentially antagonistic concentrations of cyclopentenyl uracil (CPEU) 
[12], the CPEC dosage was divided into three consecutive intraperitoneal injections administered 
over 2 h.Twenty-four hours after the last CPEC injection, rats were injected with approximately 75 
MBq 99mTc-Annexin V. One hour thereafter pinhole SPECT scintigraphy was performed. After the 
scintigraphy the rats were killed by cervical dislocation. Serum was taken for analysis of troponin 
T (serum was stored at 20°C in accordance with the manufacturer’s instructions). Hearts, blood, 
and sections of liver, fat, muscle, kidney, spleen were weighed and radioactivity counted using 
a multichannel analyser. Hearts were further processed for histological examination. To study 
whether cardiotoxicity would occur later than 24 h and therefore might not be detected in the 
first six groups, an extra group of nine rats received 90 mg/kg CPEC and a SPECT scintigram with 
99mTc-Annexin V was performed on days 1, 3, 6 and 8 after CPEC administration. Rats were 
killed after the scintigraphy on day 8 and further processed as described above.
Annexin labelling
Human annexin V was produced by expression in Escherichia coli as described elsewhere [13]. 
The purified protein was derivatized with hydrazinonicotinamide (Hynic) [14]. To bind 99mTc to 
the Hynic-annexin V conjugate, 0.8 ml containing approximately 1,000 MBq pertechnetate was 
added. Subsequently, 0.02 ml of freshly prepared stannous tricine was added to the solution. 
The reaction vial was incubated for 15 min at room temperature. Radiochemical purity was 
determined chromatographically using instant thin-layer chromatography. Labelling efficiency 
was consistently above 92%, providing a specific activity of 7.4 MBq/g protein. Under these 
conditions, annexin labelling was stable for at least 4 h.
Camera design
For imaging of 99mTc-annexin V uptake in the rat heart, a gamma camera (Philips ARC3000) 
situated in a dedicated animal care facility was equipped with a small animal SPECT (single 
photon emission computed tomography) gantry and a pinhole collimator fitted with a 3-mm 
tungsten aperture [15]. Compared with planar imaging, SPECT gives a higher contrast and better 
localization. The gamma camera is interfaced to a NUD (Nuclear Diagnostics, Stockholm, Sweden) 
Hermes acquisition and processing station. SPECT acquisition of the thorax was performed for 
30 min at the 140 keV 99mTc-peak with a 20% window in a 64x64 matrix (50 projections, 30 s 
per projection).
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Scintigraphy and interpretation
The animals were sedated with ketamine and xylazine i.m. (40 and 2 mg/kg, respectively). Once 
sedated, the rats were injected with 75 MBq 99mTc-Annexin (40 µg/kg protein) intravenously 
in a tail vein (24 h after last CPEC injection). The animals were scanned 1 h after injection 
of the radiopharmaceutical. A region of interest (ROI) was drawn around the uptake in the 
heart. A second ROI was drawn in the lung. A cardiac uptake ratio (CUR) representing specific 
uptake of 99mTc-Annexin in the heart region vs uptake in lung was calculated according to the 
formula [(mediastinum lung)/lung]. A semi-quantitative assessment was preferred over visual 
interpretation.
Histology
After removal the hearts were fixed for 4 h in ice-cold freshly dissolved 4% paraformaldehyde in 
PBS (10 mmol/l NaH2PO4/Na2HPO4 and 150 mmol/l NaCl, pH 7.4) and subsequently transferred 
to 70% ethanol. Hearts were dehydrated in a graded ethanol series, and embedded in Paraplast. 
Hearts were sectioned at 7 µm and mounted on polylysine-coated slides. Slides were histologically 
stained (haematoxylin-azophloxin) or used for apoptosis detection. Detection of the early phase 
of apoptosis was performed by immunohistochemical staining using an antibody directed 
against cleaved caspase 3 (1:100 diluted) or cytochrome C (1:5,000 diluted). Antibody binding 
was visualized using the unconjugated peroxidase technique previously described [16]. The 
myofibroblasts marker a-SMA (1:4,000 diluted) was used as a positive control; negative control 
consisted of replacing the primary antibody with PBS. Detection of the late phase of apoptosis 
was performed by the TUNEL assay, according to the manufacturer’s instructions [17].
Statistical analysis
Differences between several independent groups were analysed by the non-parametric Kruskal-
Wallis test. Differences between two independent groups were analysed by the non-parametric 
Mann-Whitney test. Results are expressed as mean ± SD. All statistical tests were two-tailed and 





Effect on frequency and contractility
No effect on frequency was observed after CPEC incubation of right atria. The frequency was 
observed on line, but not registered. The profiles of right atria exposed to CPEC were similar 
to those of untreated atria in this experimental setting (frequency 190-240 beats per minute). 
Correct measurement of contraction force could be obtained from 17 of the 18 left atria (six 
control, five exposed to 0.1 mol/l CPEC, six exposed to 1 mol/l CPEC). As shown in Fig. 1a, 
a trend towards a decrease in contraction force with increasing CPEC dosage was observed. 
However, the differences were not significant. The decrease in contraction force corresponded to 
an increase in CPEC-TP concentration and a decrease in CTP levels (Fig. 1b).
1a                           1b
Figure 1a 
Influence of CPEC on contraction force in rat atria (difference from initial contraction force in mN) showing a trend in 
decrease of contraction force after CPEC treatment. b The corresponding CPEC-TP and CTP concentrations in the atria are 
represented
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Apoptosis
Representative scintigraphic images obtained from control and treated rats are shown in Fig. 2. 
2a         2b
Figure 2 Pinhole SPECT scintigraphy of a CPEC-treated rat
(90 mg/kg) (a) and a control rat (b), 1 h after i.v. injection of 75 MBq 99mTc-Annexin V. On the images of the thorax (anterior 
view, coronal) including a part of the liver (A), the physiological distribution of the radiopharmaceutical, with prominent 
uptake in the liver and moderate remaining blood pool activity in the mediastinal region, is shown. The white lines indicate 
the contours of the rat, regions of interest are drawn around the cardiac region (1) and the lung (2) for determination of the 
cardiac uptake ratio. No significant differences were found between cardiac uptake ratio for control and treated rats
On scintigraphy, rats showed faint mediastinal uptake, representing circulating blood pool and 
bone marrow uptake. No increase in cardiac uptake ratio was observed (Fig. 3) after CPEC 
dosage. 
Figure 3 Annexin uptake 
Cardiac uptake ratio in control animals versus rats treated with 
CPEC (mean + 2SD), no significant differences in cardiac 
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Scanning at later intervals or giving an extra dose of CPEC, did not result in higher uptake ratios. 
This corresponded with the results obtained after counting of radioactivity in blood and cardiac 
samples. No significant differences were seen in the uptake ratios of heart vs blood, nor heart vs 
lung (data not shown).
When correcting the counted activity in blood for the injected dose, higher blood activity was 
found for the 90 mg/kg dose group (P=0.001), no significant differences between blood activity 
were found for the other groups (Fig. 4). General histological staining of heart sections using 
routine histological staining procedures did not reveal any gross morphological abnormalities 
(haematoxylin-azophloxin staining) (Fig. 5). A few late apoptotic cells could be identified using 
the TUNEL assay in the highest dose group (Fig. 6). Late apoptotic cells were not identified in 
controls and rats treated with 60 mg/kg. Staining for the early apoptosis markers caspase 3 and 
cytochrome C did reveal a few caspase 3 positive cells in controls and in hearts of rats treated with 
90 mg/kg. However, the amount of apoptotic cells was very small and not enough to differentiate 
between control and treated hearts (Fig. 6). Moreover, no increase was observed after two cycles 
of CPEC. No cytochrome C pattern indicating apoptosis was detected.
Figure 4 Activity in blood
Radioactivity in the blood of control animals and of rats treated with CPEC. Activity in blood was corrected for sample weight, 
animal weight and injected dose. Blood from rats treated with 90 mg/kg CPEC showed significantly higher blood activity. This 
might indicate slower Annexin V clearance in this group
Based on these results it was considered unlikely that the lower dosage groups would show a 
different pattern, therefore they were not histologically examined. Troponin T concentrations were 
determined in rat serum. As shown in Fig. 7, no differences in troponin T levels could be observed 
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Figure 5 
Haematoxylin-azophloxacin staining of the heart 
(four-chamber view) of a rat treated with 90 mg/
kg CPEC, showing no gross abnormalities
Figure 6
A late apoptotic cell, detected by the TUNEL assay, in the septum of a heart treated with 90 mg/kg is shown in A, whereas in 
the heart of a control rat no apoptotic cells were present. In B, a detail of the septum of a control rat is shown. Early apoptosis 
was detected by using antibodies against caspase 3. A few early apoptotic cells were found in rats treated with CPEC and 
in control rats. The number of early apoptotic cells was too small to differentiate between controls and treated rats. C and D 
show early apoptotic cells in a detail of the septum of a heart treated with 90 mg/kg CPEC (C) and a control heart (D). All 









Figure 7 Cardiac Troponin T level
The serum level of the cardiac (necrosis) marker troponin T was measured (µg/l). No significant differences between cardiac 
troponin T levels were found. The detection limit of the assay was 0.04 µg/l
DISCUSSION
Cardiotoxicity occurs during therapy with several cytotoxic drugs and may be the dose-limiting 
factor in cancer treatment and hence tumour response. Furthermore, cardiotoxicity can also 
be responsible for long-term side- effects and may cause severe morbidity in surviving cancer 
patients [18], which may be relevant, especially in pediatric oncology patients. Cardiotoxicity 
from anthracycline treatment is known to have high prevalence. The events in the phase I study 
of Politi et al [1] suggested that new drugs like CPEC may also have cardiotoxic effects. The 
symptoms were characterized by (irreversible) hypotension. Hypotension can have vascular 
or myocardial causes. By acting on endothelial receptors, stimulating synthesis and release of 
EDRF/NO, vasodilatation may occur [19]. This usually is an acute effect and as the hypotension 
in the clinical trial occurred 24-48 h post-infusion, an acute vasodilative effect of CPEC was 
considered less probable. Moreover, postmortem examination in one of the patients in the phase-
I trial, showed signs of subendocardial necrosis. We therefore choose to investigate possible 
cardiac effects of CPEC. We hypothesized that the hypotension might be caused by a decrease in 
contraction force of the heart. Although we observed a trend in decrease of contraction force, the 
in vitro experiments on rat atria did not show an acute effect on the heart rate. This is especially 
true when considering that the concentrations used in our in vitro experiments to study the effects 
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on the contraction force were 0.1 and 1 mmol/l CPEC. The most elevated concentration used 
in humans in the phase-I trial was 0.01 mmol/l [1]. Even if a clinically relevant effect in our 
experiments had been found, the effect in humans would probably be more attenuated, because 
much lower concentrations of CPEC were used. The fact that the active metabolite CPEC-TP could 
be measured in the heart tissue indicates that the absence of a clinical effect was not caused by 
inadequate metabolism in the in vitro model used. Furthermore, a decrease in CTP concentrations 
was observed after increasing CPEC dosages, showing the desired biochemical effect of CPEC. 
The limitation of in vitro experiments as performed in this study is the relatively short exposure 
time (1.5 h) of the atria to CPEC. Because the hypotension in the clinical trial was observed 
after 24-28 h, the exposure might have been too short to obtain toxic effects. However, if cardiac 
damage was the cause of the hypotension in the clinical study, it is also conceivable that there is 
a time lag between early cardiac effects and the finally observed hypotension.
Because cardiotoxicity is a well-known side-effect of the anthracyclines, a tremendous amount of 
research is focussing on the mechanism of this side-effect. Studies indicate that the myocardial 
damage caused by the anthracycline drug doxorubicin involves apoptosis. This programmed cell 
death process would, for anthracyclines, be initiated by the formation of oxidative free radicals. 
Apoptotic cell death was indeed found in rat cardiomyocytes and bovine aortic endothelial cells 
upon exposure to doxorubicin [5, 20] and could be imaged in vivo in a rat model with 99mTc-
Annexin V [11]. Although there is no structural relationship between doxorubicin and CPEC, CPEC 
is also associated with apoptosis and, therefore, we investigated the apoptosis-inducing potential 
in the heart. Our results with 99mTc-Annexin V suggest no cardiac involvement of apoptosis 
after CPEC treatment. Cardiac uptake ratios with scintigraphy were not increased upon CPEC 
treatment, neither were ratios of heart-to-blood activity. The measured cardiac uptake ratio with 
scintigraphy was probably due to activity in circulating blood. Ohtsuki et al [21]have reported that 
residual blood activity in mice 1 h after injection was about 5% of the injected dose. Delaying 
imaging to reduce blood pool activity was not considered in our study, because the late-phase 
plasma clearance is slow and image-count statistics would decrease because of radioactive decay. 
The timing of scintigraphy of 60 min after intravenous injection of 99mTc-annexin was based 
upon a previous study of a doxorubicin cardiotoxicity model in the rat [11]. Annexin V has a short 
half-life in the circulation without significant redistribution after 30 min, enabling radionuclide 
imaging within 1 h of injection [22]. Blood activity was increased in the group treated with 
the highest CPEC dose (90 mg/kg), and this might indicate slower clearance because of renal 
toxicity in this group. However, as creatinin levels were not measured in our study we cannot 
confirm this assumption. In earlier toxicity studies kidney toxicity was observed in mice after CPEC 
treatment in a single-dose toxicity study (CPEC dose: 0-140 mg/kg). However, no kidney toxicity 
was observed in rats (maximum dose: 70 mg/kg) (data on file at the National Cancer Institute, 
Bethesda, MD, USA). The doses we used were based on these previous toxicity studies, where 
the lowest dose (20 mg/kg) was shown not to be toxic as a bolus. Our highest dose (90 mg/kg) 
was 20 mg/kg higher than the maximum dose used.
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Because results from the group that was scanned on several consecutive days after CPEC treatment 
were not different from those from other groups, it is unlikely that the absence of increased 99mTc-
annexin V uptake in the heart was due to the short interval between injection of CPEC and 99mTc-
annexin V (24 h). Cumulative dosage does not seem to be of influence, because administration 
of two CPEC dosages did not give an increase in 99mTc-annexin V uptake in the heart. In earlier 
experiments with doxorubicin [11] the detection level of apoptosis with 99mTc-annexin V, seemed 
to be higher than with the TUNEL assay. In order to investigate whether this might have been 
of influence in our study, we also performed histological apoptosis assays. Late and early-phase 
apoptosis was investigated. Our results from histology correspond with the absence of difference 
among the dose groups in radioactive cardiac uptake ratios. The TUNEL assay was used to detect 
the late phase of apoptosis. In the clinical phase-I trial, cardiotoxicity was observed 24-48 h after 
CPEC treatment. Because 99mTc-annexin V visualizes an early (preclinical) phase of apoptosis, 
we performed scintigraphy 24 h after the last CPEC injection. This might be too early to detect 
late-phase apoptosis, as is done with the TUNEL assay. Therefore, we also performed histological 
staining with two early phase markers: cleaved caspase 3 and cytochrome C. Activation of caspase 
3 occurs early in the apoptotic pathway and leads, among other effects, to the externalization 
of PS and fragmentation of several cytoplasmic proteins and nuclear DNA. Caspase 3 can either 
be activated by cytokines and upstream caspases (e.g. caspases 1 and 8) or by mitochondrial 
(or oxidative) stress. The stress leads to the release of cytochrome C and processing of caspase 
9, which subsequently activates caspase 3 [23]. As well as with the TUNEL assay, no massive 
apoptosis could be observed in CPEC-treated rats after immunostaining with cleaved caspase 3 
or cytochrome C.
Studies with cytotoxic drugs have shown involvement of apoptosis and necrosis [23-25]. Therefore, 
we also investigated whether necrosis was involved in possible CPEC cardiotoxicity. Serum levels 
of cardiac troponin T were determined. Cardiac troponin T (cTnT) is a cardiac-specific marker 
for monitoring necrotic cardiomyopathy. The gene expression is restricted to striated muscle, 
principally cardiac muscle, and cTNT is released relatively rapidly into the blood. The cTNT 
immunoassay used for detection of myocardial injury in people is able to detect blood activity in 
rat after toxic, ischaemic and immunologic injury to myocardium [26]. In our study cTNT levels 
were not increased after CPEC treatment, suggesting that necrosis does not play a significant role 
in the possible cardiotoxicity. 
Recently, Kostin et al [27] have reported autophagy as a third form of cell death in human 
myocytes. Whether this also occurs in rats treated with CPEC remains unclear, because this form 
of cell death is not detected by the methods we used.
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In the present study we were not able to reproduce significant (semi)-acute cardiotoxicity of CPEC 
as observed in the phase I clinical trial. The rat model with 99mTc-Annexin V was an adapted 
version of a model that has been used successfully to detect doxorubicin- induced apoptosis in the 
heart [11]. Our results seem to suggest that apoptosis does not play a significant role in CPEC-
induced cardiotoxicity. It remains unclear what caused the severe hypotension in the phase-I trial 
and whether or not this was a true cardiotoxic effect.
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Chemotherapy with anthracyclines is associated with cardiotoxicity. Besides known risk factors 
such as cumulative dose and mediastinal irradiation, there are indications that genetic variation 
might also be associated with the development of anthracycline induced cardiotoxicity. In the 
current study a retrospective case control analysis was performed in oncology patients having 
received anthracyclines. Allele frequencies of genetic polymorphisms in several candidate genes 
between patients with and without anthracycline-induced cardiotoxicity and between cases and 
healthy control subjects were studied. Anthracycline-induced cardiotoxicity was associated with 
the T7508A variant in the GTPase Rac2, a gene with a known functionality in NAD(P)H oxidase 
activity. Furthermore, we tested in vitro in a rat cardiomyocyte cell line (H9c2), whether the 
anthracycline doxorubicine and the cytotoxic and cardiotoxic drug cyclopentenyl cytosine (CPEC) 
influenced the expression of the candidate genes (p22phox, Rac2, MRP1 and MRP2), that 
were reported earlier to be related with doxorubicin-induced cardiotoxicity. CPEC caused a small 
decrease in the expression of MRP2 and did not influence the expression of the other genes. The 
expression of MRP1 was decreased after incubation with doxorubicin whereas no changes were 
found in the expression of Rac2, p22phox and MRP2. 
It is concluded that although the expression of Rac2 did not seem to be influenced by 
doxorubicin, a SNP in the GTPase Rac2 was associated with anthracycline induced cardiotoxicity. 
As demonstrated by their influence on MRP1 and MRP2 respectively, doxorubicin and CPEC 
decreased the expression of genes involved in multi drug resistance. 
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INTRODUCTION
Cardiotoxicity is associated with several cytotoxic drugs, among which the anthracyclines seem 
to be the most important group and much research has been done with anthracyclines to unravel 
the mechanisms behind this severe side effect [1-4]. Oxidative stress caused by reduction of 
doxorubicin seems to play an important role in the pathogenesis. Several risk factors such as age, 
mediastinal irradiation and cumulative dose have been associated with anthracycline induced 
cardiotoxicity. Of these, cumulative dose seems to be the most important risk factor [5,6]. The 
incidence of doxorubicin induced cardiomyopathy and congestive heart failure increases from 
approximately 3-5% below 400 mg/m2 to 20-50% at 700 mg/m2 [7,8]. A maximum cumulative 
dose of 450-550 mg/m2 for doxorubicin is nowadays commonly accepted. Depending on their 
cardiotoxic potential, maximum cumulative doses are also established for the other anthracyclines 
[9]. However, as indicated by the 5% of patients with cardiotoxicity having received 400 mg/m2 
doxorubicin or less, there is a category of patients still developing cardiotoxicity upon low to 
normal cumulative doxorubicin doses. 
These inter-individual differences may have a genetic cause and several mechanisms are 
conceivable that could explain this relationship. One mechanism might be found in the oxidative 
stress theory. As oxidative stress seems to play an important role in the development of the 
anthracycline induced cardiotoxicity [1-3], changes in enzymes involved in oxidative stress may 
result in more or less susceptibility for anthracycline induced cardiotoxicity. The NAD(P)H oxidase 
multi-enzyme complex is an important source of reactive oxygen species in the myocardium 
[10]. Indeed, recently Wojnowski et al reported associations between polymorphisms in the 
NAD(P)H oxidase multi-enzyme complex and cardiotoxicity of doxorubicin [11]. They used a 
candidate gene approach to detect associations between cardiotoxicity and single nucleotide 
polymorphisms (SNPs). Besides the three SNPs in genes related to the NAD(P)H oxidase complex 
(p22phox, p40phox and Rac2), two SNPs in genes coding for the drug efflux pumps MRP1 and 
MRP2 (multidrug resistance protein 1 and 2) were also associated with doxorubicin induced 
cardiotoxicity. Anthracyclines are known substrates for the efflux transporter MRP1 [12,13], and 
polymorphisms of this pump are described in other studies [14,15]. 
Apparently the five genes studied by Wojnowski et al are involved in the mechanisms behind 
doxorubicin induced cardiotoxicity. However, NAD(P)H oxidase and the efflux pumps both are 
not exclusively related to the function or metabolism of doxorubicin. It is therefore conceivable 
that changes in these genes are also related to cardiotoxicity induced by other cytotoxic drugs. 
The experimental cytotoxic drug cyclopentenyl cytosine (CPEC) has also been associated with 
cardiotoxicity and until now the mechanism has not been clarified [16, 17]. CPEC is a nucleoside 
analogue structurally related to the cytotoxic drugs cytarabine and gemcitabine. These drugs are 
not thought to be substrates nor modulators for MRP1. Substrates for MRP2 are supposed to 
be similar to those for MRP1, however, there is little information available upon modulators for 
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MRP2 [18]. If CPEC would be able to modulate MRP2 by altering its expression, this might be 
involved in CPEC induced cardiotoxicity. 
In the present study we aim to replicate the results of the study by Wojnowski et al in a case 
control study. Moreover, in order to further investigate the association of the candidate genes and 
cytotoxic drug induced cardiotoxicity, we have also investigated in a rat cardiomyocyte cell line 
(H9c2), the expression of the candidate genes upon incubation with the anthracycline doxorubicin 
and the experimental cytotoxic drug CPEC.
MATERIAL AND METHODS
Study population 
We retrospectively selected study subjects by reviewing all patients with cancer (n=1074) that 
received doxorubicin between january 1999 and april 2005. Patients were included in this study 
if they were subjected to routine cardiac assessment (either by left ventricular ejection fraction 
(LVEF) measurement or echocardiography) and if DNA was available. Cases could also be directly 
selected by the participating physicians if the patients were known for clinically overt anthracycline 
induced cardiotoxicity. Patient material was obtained from blood samples from routine control and 
was coded before analysis in order to prevent results from being related to individual patients. The 
protocol was approved by the institutional Medical Ethical Committee.
Based on the described selection a group of cases (n=11) and the first control group (n=26) 
were determined. The first control group consisted of patients without reported cardiotoxicity, 
for criteria see below. Most patients had received doxorubicin, if patients had received another 
anthracycline (2 of the cases: one received daunorubicin and mitoxantrone, the other received 
doxorubicin and daunorubicin, 1 control patient received epirubicin and doxorubicin), the received 
cumulative dose of that anthracycline was converted to the equivalent cumulative doxorubicin 
dose. The conversions were based on the different maximal cumulative dosages which were 
respectively 450-550 mg/m2 for doxorubicin, 500-600 mg/m2 for daunorubicin, 850-1000 mg/
m2 for epirubicin and 160-200 mg/m2 for mitoxantrone [9]. For example, 420 mg of epirubicin 
was converted to 227 mg of doxorubicin (420 * 500/925 = 227). Patients having received more 
than 550 mg/m2 of cumulative doxorubicin dose were excluded from the analysis.
The second control group consisted of a panel of 180 healthy volunteers. The DNA of these 
subjects was previously selected in families of patients who had had meningococcal disease[19] 
and in subjects who served as healthy controls to study the susceptibility to systemic lupus 
erythematosus [20]. 
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Cardiotoxicity assessment
Cardiotoxicity was determined for the group of cancer patients and was based on the following 
criteria: clinically overt cardiotoxicity or a decrease in left ventricular ejection fraction (LVEF) of 
more than 20% or a decrease of more than 10% resulting in a LVEF below 50% [8]. If assessment 
of cardiac condition was performed by echocardiography, cardiotoxicity was defined as a decrease 
of more than 10% or a decrease resulting in a shortening fraction (SF) below 30% [21]. 
Sample preparation and measurement of SNPs
Six SNPs in five candidate genes were selected that had been associated with doxorubicin induced 
cardiotoxicity in a previous study [11]. Three selected genes had a relation with the NAD(P)H 
oxidase multi-enzyme complex: those encoding for the GTPase Rac2, the subunit p40phox 
(NCF4) and the subunit p22phox (CYBA) from the NAD(P)H oxidase multi-enzyme complex. The 
other genes were encoding for MRP1 and MRP2. The following SNPs were analyzed: p40phox 
212A>G (rs1883112), p22phox His72Tyr (rs4673), Rac2 7508T>A (rs13058338), MRP1 
Gly671Val (2012G>T), MRP2 Val1188Glu (rs8187694), MRP2 Cys1515Tyr (rs8187710). The 
SNPs for p22phox, MRP1 and MRP2 were non-synonymous. The genes encoding for Rac2 and 
NCF4 were both found on chromosome 22, p22phox and MRP1 on chromosome 16 and MRP2 
on chromosome 10.
Table 1 primer sequences used for SNP assay



















* Primers are Biotine labeled at 5’-end
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DNA was isolated from peripheral blood cells by a standard manual salting-out method. Sterile 
water was used as a negative control. Genotyping was performed using real-time polymerase chain 
reaction with TaqMan (MRP1) (Applied Biosystems, Nieuwerkerk aan de IJssel, The Netherlands) 
or Pyrosequencer (Isogen Lifesciences, Maarssen, The Netherlands) (other SNPs) according to 
manufacturer’s instructions. In table 1 the sequences of the primers are displayed. 
Statistical analysis
Differences in baseline characteristics between the cancer patients were analyzed by Student’s 
t-test (continuous variables) or chi-square test (dichotomous variables). P values less than 0.05 
were considered significant. For association with cardiotoxicity, differences in genotype distribution 
were tested by 3 x 2 cross tabulations for each genotype with analysis by Fisher’s exact test, and 
by 2 x 2 cross-tabulations for allele carriers versus noncarriers with calculation of the odd’s ratios 
(95% confidence interval). Binary logistic regression with mediastinal irradiation as a covariate 
was used to test whether mediastinal irradiation had to be considered as a possible confounder.
All statistical analysis were performed using SPSS 12.0.1 software (SPSS, Chicago, USA). 
Cellular experiments 
The rat cardiomyocyte cell line H9c2 (ECACC, Wiltshire, UK) was used for in vitro assays. This 
cell line has been used before to study anthracycline induced cardiac injury [22-24]. The ability of 
doxorubicin and CPEC to change the expression of the candidate genes was explored. Cells were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; Cambrex Corporation, East Rutherford, 
NJ, USA) containing 2mM L-glutamine, 100 IU/ml penicillin G, 100 µg/ml streptomycin and 10% 
fetal calf serum (Invitrogen, Breda, The Netherlands). Cells were not allowed to reach more than 
70% confluency.
For determination of cytotoxicity cells were plated in 96-well plates (approximately 20 x 103 cells 
per well). After 24 hours incubation at 37ºC in a humidified environment of 5% CO2, cells were 
exposed to different concentrations of doxorubicin (0 – 10 µg/ml) (Pharmachemie, Haarlem, The 
Netherlands) and CPEC (0-1 µg/ml) (kindly provided by the National Cancer Institute, Maryland, 
USA) for 24 hours. After incubation with the active ingredient, medium was replaced and cells were 
further cultured for 72 hours. Cytotoxicity was determined by the sulforhodamine B (SRB) assay as 
described earlier [25,26]. Briefly, after drug treatment, cells were fixed with 100 µl thrichloroacetic 
acid (10%) for 60 minutes at 4ºC, washed with water and stained with 100 µl SRB (0.4% in 1% 
acetic acid) for 30 minutes at room temperature. Then plates were rinsed with acetic acid (1%) 
and 200 µl Tris base (10mM, pH 10.5) was added. Optical density was determined at 560 nm in 
each well in a microplate reader (Softmax, Biorad, Veenendaal, The Netherlands). 
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For the expression assays H9c2 cells were treated with doxorubicin 1 µg/ml or CPEC 1 µg/ml for 
4 or 24 hours (in triplo). At these concentrations approximately 90% of the cells were still viable 
during the incubation time (4 to 24 h). Total RNA was isolated from the cells using the mini 
RNeasy total RNA isolation kit (Qiagen, Venlo, The Netherlands) and the protocol supplied by 
the manufacturer. The isolated RNA was converted to cDNA using standard techniques. cDNA of 
Rac2, p22phox, MRP1 and MPR2 were analyzed by RT-PCR on the Taqman 7500 in duplo using 
SYBR green (Applied Biosystem, Nieuwerkerk aan de IJssel, The Netherlands). The sequences of 
the used primers are described in table 2. The expression of β2-microglobuline gene was used as 
an internal control, which had been proven to be stable expressed in these experiments.
The relative changes in gene expression were calculated with the 2-∆∆Ct method With this method 
data are presented as the fold change in gene expression normalized to the endogenous control 
gene (β2-microglobuline) and relative to the untreated control at the same time interval. The 
range in fold change is determined by calculating respectively the fold change out of the average 
∆Ct + SD and ∆Ct – SD [27].
Table 2: primer sequences used for expression assay













The characteristics of the cases and the first group of control (cancer) patients are represented 
in table 3. Cases were (non significantly) more frequently irradiated in the mediastinal region. 
However, when mediastinal irradiation was used as a covariate in the statistical analyses, this 
was of no relevance for the odd’s ratios for the calculated differences between cases and controls 
for the SNPs that were analyzed. Therefore, we concluded that mediastinal irradiation did not 
confound our analysis.
Table 3 Patient characteristics
 cases (n=11) controls (n=26)
Gender, M/F 1/10 13/13
Age in years(SD) 36 (19) 42 (16)
Range in age 13-69 21-73
Cumulative doxorubicin dosein mg/m2 (SD) 399 (93) 332 (113)
Mediastinal irradiation 5 6
Disease
Sarcoma* 6 13
Mamma carcinoma 2 3
Acute Myeloid Leukemia (AML) 2 0
Non Hodgkin Lymphoma (NHL) 1 3
Hodgkin Lymphoma (HL) 0 6
M Kahler 0 2
*different forms of sarcoma's: ewing, osteo, synovium, bone-leiomyo
There were no statistic differences between the two groups in age, cumulative dose or mediastinal irradiation.
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No significant associations with cardiotoxicity were found for the p40phox 212A>G, p22phox 
His72Tyr, MRP1 Gly671Val, MRP2 Val1188Glu and MRP2 Cys1515Tyr polymorphisms between 
either cases and control patients or healthy subjects. Combinations of SNPs based on either 
the location on the same chromosome (Rac 2 with p40phox, p22phox with MRP1 and both 
SNPs in MRP2) or physiological role (Rac2, p40phox and p22phox) neither showed a significant 
association with cardiotoxicity.
A significant association with cardiotoxicity was found for the SNP in Rac2. Frequency of the A 
allele was significantly lower in healthy subjects compared to cardiotoxic cancer patients (35% 
versus 82%) with an odds ratio of 0.12 (0.03-0.58). Distribution in the control patient group was 
in line with this observation (57% versus 82%), although it reached not significance (odds ratio 
0.29, range 0.05-1.65). 
Cells
In table 4 the relative fold expression changes with their ranges are presented for the genes 
studied. The expression of MRP1 was approximately 3 fold decreased upon 24 hr exposure of 
doxorubicin (mean fold change 0.32, range 0.18-0.57), see figure 1. No changes in expression 
were seen after 4 h of incubation. The expression of the other genes remained unchanged after 
treatment with doxorubicin both after 4 and 24 h of incubation. Although the range in fold change 
was relatively large, CPEC seemed to decrease the expression of MRP2 after a 24 h incubation 
period (mean 0.49, range 0.25-0.85), no changes were seen after 4 h of incubation. CPEC did 
not induce changes in expression of the other genes (4 and 24 h of incubation). 
Table 4 Relative fold changes in expression upon exposure to doxorubicin or CPEC
normalized fold change (2-∆∆Ct) relative to untreated control (range)
Doxorubicin 24 hr Doxorubicin 4 hr CPEC 24 hr CPEC 4 hr
MRP1 0.32 (0.18-0.57) 0.79 (0.31-1.45) 0.81 (0.39-1.30) 0.94 (0.34-2.30)
MRP2 0.55 (0.23-1.09) 0.68 (0.28-1.12) 0.49 (0.24-0.85) 0.98 (0.46-2.34)
Rac2 0.61 (0.23-1.14) 0.71 (0.19-1.77) 0.54 (0.21-1.16) 0.88 (0.27-2.93)
P22phox 0.85 (0.28-1.27) 1.14 (0.45-2.37) 1.03 (0.53-1.80) 1.11 (0.56-2.5)
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Figure 1 Fold change in expression of MRP1 relative to untreated samples 
In the figure the fold change in expression of MRP1 relative to the untreated samples is presented. The four bars indicate the 
different treatments (e.g. doxo 4 means treatment with doxorubicin for 4 h). After 24 h of incubation with doxorubicin the 
expression of MRP1 is approximately 3 fold decreased compared to the untreated samples.
DISCUSSION
In the present study we have used two approaches to investigate the association between five 
candidate genes (p22phox, p40phox, Rac2, MRP1 and MRP2) and cytotoxic drug induced 
cardiotoxicity. First we studied SNPs in these genes in a retrospective case control study and 
secondly we investigated whether the expression of these genes changed upon incubation with 
doxorubicin or CPEC. 
The five candidate genes were selected based on a study by Wojnowski et al. In a population of 
non-Hodgkin patients they found an association between 6 SNPs in five genes related with either 
NAD(P)H oxidase enzyme complex (p22phox, p40phox and Rac2) or multidrug efflux pumps 
(MRP1 and MRP2) and doxorubicin induced cardiotoxicity [11]. There is very little information 
on the functional analysis of the SNPs studied. For the SNP in p22phox (CYBA) conflicting results 
regarding its influence on NAD(P)H oxidase are published [28,29]. The SNP in MRP1 is located 
near the ‘Walker A motif’ and studies suggest that mutations near this motif would be able to 
decrease the activity of the efflux pump [14,15]. For the other SNPs no data in the published 
literature are available. 
In our study we have been able to reproduce the association as reported earlier by Wojnowski et al 
between the SNP in the Rac2 gene in cancer patients experiencing anthracycline induced chronic 
cardiotoxicity when compared with a healthy population. 
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No difference between cancer patients with and without cardiotoxicity was found in our study, 
although the difference in allele frequency observed for Rac2 was in line with the observed 
statistical difference between cases and the healthy population. There were no statistical 
differences between the cases and the patient control group in the known risk factors cumulative 
dose and mediastinal irradiation. Several patients had received cyclophosphamide which has 
also been associated with cardiotoxicity, but there was no statistical difference between the two 
groups. Moreover, little information is known about prevalance, risk factors and mechanism of 
cyclophosphamide induced cardiotoxicity [6]. There were significantly more female patients in the 
case group, however, gender is not a known risk factor for anthracycline induced cardiotoxicity. 
We did not observe associations between the other SNPs and cardiotoxicity. Our patient population 
probably was too small to detect differences as reported by Wojnowski et al [11]. In that study 
83 patients with doxorubicin induced cardiotoxicity were evaluated whereas in the present 
study 11 cases were included. However, the cases in our study were selected out of a group of 
1074 patients treated with anthracyclines in our large academic medical center in a 6.5 years 
period, indicating the low frequency of overt anthracycline induced cardiotoxicity. Indeed, a crude 
incidence of approximately 1.1% of anthracycline induced cardiotoxicity can be estimated from 
our cohort which is in line with published incidence rates being approximately 3-5% [7,8]. This 
observation also implicates that, when implementing (with the current knowledge) a diagnostic 
screening aimed at detecting patients at increased risk for anthracycline induced cardiotoxicity, 
would result in an unrealistically high number needed to genotype. 
Besides the analysis of the SNPs, our second approach to investigate the association between 
the candidate genes and cardiotoxicity consisted of determining the influence of the cytotoxic 
drugs doxorubicin and CPEC on the expression of the genes. As little information on the functional 
analysis of the SNPs is yet available, this might help to clarify the role of the genes and the 
specific SNPs. 
The NAD(P)H oxidases are involved in the formation of reactive oxygen species. More NAD(P)H 
activation leads to more superoxide formation and this may result in increased cardiotoxicity. 
Rac2 is essential for stimulation of the NAD(P)H oxidase [30] and is mainly expressed on cells 
from hematopoietic system, however the Rac2 protein has also been detected on rat enterocytes 
[31] and human aortic smooth muscle cells [32]. A decreased expression of Rac2 may result in 
a less activated NAD(P)H oxidase. Wojnowski et al have shown that mice with reduced NAD(P)H 
oxidase activity experienced less cardiotoxicity after treatment with doxorubicin [11]. The protein 
p22phox (CYBA) is necessary in NAD(P)H activation [33,34]. Based on their different roles, an 
increased expression of Rac2 (SNP rs13058338) and p22phox (SNP 4673) upon incubation 
with doxorubicin might be expected. However, we did not reveal any significant changes in the 
expression of both genes upon exposure to doxorubicin and CPEC when compared to the untreated 
cells. Rac2 was weakly expressed (Ct values between 30 and 34) in the H9c2 cells, which might 
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explain the relatively large range in fold change. However, p22phox had a higher expression (Ct 
values between 22 and 24) and the range was still relatively large suggesting that other influences 
might have played a role as well. 
Expression of multidrug resistance proteins in tumor cells is associated with resistance to 
anthracyclines [18,35]. An impaired function of MRP1 might be associated with higher 
anthryacycline levels in the heart, rendering it more susceptible to the detrimental effects of 
anthracyclines. The reduced expression of MRP1 that was detected in our study after 24 hr 
incubation with doxorubicin seems to confirm this hypothesis. Apparently doxorubicin needs time 
to exert its influence on the expression of MRP1, as no difference with the untreated samples 
was detected after 4 h of incubation. Earlier reports on human small cell lung cancer cell lines 
[36] and heart tissue of mice [37], showed an increase in MRP1 expression after treatment 
with doxorubicin. In the study with the human small cell lung cancer cell line, c-jun N-terminal 
kinase activation (JNK) seemed to be essential for the induction of MRP1 by doxorubicin [33]. 
It is conceivable that JNK acts differently in H9c2 cells. The fact that the results of the two 
studies were obtained in different tissues or species might therefore have been responsible for the 
apparently conflicting results on MRP1 expression by doxorubicin. 
CPEC did not influence the expression of MRP1, which might be partly explained by its chemical 
structure. CPEC is a nucleoside analogue and has structural similarities with the cytotoxic drugs 
cytarabine and gemcitabine and both drugs are not thought to be either substrates nor modulators 
of MRP1 [18]. MRP2 was slightly downregulated after incubation with CPEC and although 
substrates for MRP1 also are suggested to be substrates for MRP2, there is no information 
available upon modulators of MRP2 [18].
In this study we evaluated the abilities of doxorubicin and CPEC to influence the expression of four 
selected genes. However, doxorubicin has also been reported to induce the expression of several 
other genes involved in heart function like endothelial nitric-oxide synthese (eNOS), atrial and 
brain natriuretic peptide (ANP and BNP) and Fas antigen, the latter being involved in apoptosis 
[38-40]. Based on the structure of CPEC it might have been interesting to investigate the influence 
on MRP4 and MRP5 as they are believed to be involved in nucleoside transport [18]. 
Moreover, it remains to be solved whether the induced damage by doxorubicin or CPEC is related 
to altered gene or whether they directly influence the expression. This illustrates the complexity 
behind the induced cardiotoxicity and changes in expression of specific genes may only partly 
explain the mechanism. 
In conclusion, in our small patient population, we have been able to detect an association between 
anthracycline induced cardiotoxicity and a polymorphism in the GTP-ase Rac2 which is associated 
with the function of the NAD(P)H oxidase complex. This is in line with the hypothesis regarding 
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the involvement of oxidative stress in the development of anthracycline induced cardiotoxicity. 
Although we did not find an association between SNPs in the efflux pumps and cardiotoxicity, 
the results of our expression study show a downregulation of MRP1 in rat cardiomyocytes after 
incubation with doxorubicin and a small decrease in expression of MRP2 after incubation with 
CPEC, suggesting that increased drug exposure of heart cells to doxorubicin or CPEC might also 
be involved in the complex mechanism of this severe side effect. 
Overall, these results suggest that genetic analysis of SNPs or genes might clarify some of the 
issues, but will probably only partly explain cytotoxic drug induced cardiotoxicity. 
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CHAPTER 9





The agent cyclopentenyl cytosine (CPEC) is a cytidine analogue with potential anti-tumor activity. 
Contrary to the newest targeted drugs, CPEC is not involved in specific intracellular signalling 
pathways or angiogenesis, but ultimately leads to inhibition of DNA synthesis and therefore could 
be classified as a classic cytostatic drug [1]. In this thesis, pharmaceutical aspects as well as 
anti-tumor activity and mechanisms of cardiotoxicity of CPEC are explored.
CPEC
CPEC can be considered as a prodrug; after transmembrane transport the drug is phosphorylated 
to form its active metabolite CPEC-TP (cyclopentenyl cytosine triphosphate). CPEC-TP inhibits 
the enzyme CTP synthetase (cytidine triphosphate synthetase) which is involved in the de novo 
synthesis of CTP out of UTP (uridine triphosphate). CTP can also be formed from the salvage 
pathway by phosphorylation of cytidine. However, several malignancies seem to have a preference 
for the formation out of UTP. Inhibition of CTP synthetase may result in depletion of CTP pools 
leading to a decrease of RNA and DNA synthesis and S-phase accumulation. Several in vitro and 
in vivo studies have shown activity of CPEC against leukemia, neuroblastoma and colorectal cancer 
[2-4]. During a phase I study in patients with solid tumors severe cardiotoxic effects was found 
[5]. However, based on the studies that showed promising results on hematological malignancies, 
plans for phase I and II clinical trials (under cardiovascular monitoring) were initiated.
DEVELOPMENT OF CPEC FOR CLINICAL USE
CPEC is only available as a raw substance and was kindly provided by the National Cancer Institute 
(Bethesda, Maryland) in the U.S.A. Formulation is an important issue during the preclinical 
development of a drug. Aspects that need to be considered with regard to drug formulation: 
stability, reconstitution and safety upon handling. These last two characteristics are especially 
important for cytostatic drugs as they often form a potential risk upon occupational exposure. As 
described in chapter 3, it is possible to formulate a sterile and stable solution of CPEC which can 
be easily administered. 
Therapeutic drug monitoring (TDM) can be useful when there is a proven relationship between 
blood levels and either toxicity or efficacy. Whether CPEC levels in humans are associated with 
efficacy is yet unclear. However, in a phase I study [5] it was shown that high concentrations of 
CPEC seemed to be associated with cardiotoxic side effects. The consequences of this finding 
are that future trials will have to start with lower dosages and that monitoring of plasma levels 
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may be required. This also means that an assay enabling monitoring of relatively low levels of 
CPEC becomes essential. Using LC-MS/MS we were able to quantitatively determine low levels of 
CPEC (chapter 4). The deaminated metabolite of CPEC: cyclopentenyl uracil (CPEU) could also 
be measured, although with a lower sensitivity. This might result in undetectable concentrations 
of the metabolite in the lower dose levels as is demonstrated by our results of the analysis of 
plasma levels of the first patient receiving low dose CPEC. However, as CPEU has almost no 
cytotoxic effects and its concentration was not associated with cardiotoxicity in the phase I study, 
no consequences are expected for the application of the assay in TDM of CPEC.
EFFICACY
The first studies with CPEC mainly focus on its activities as an antiviral agent. However, only in vitro 
studies on the antiviral activity have been published and no results in animals or humans are as 
yet known. More research has been performed on the use of CPEC as an anti-tumor agent. Activity 
against several solid tumors as well as hematological malignancies has been demonstrated in in 
vitro and in animal studies [2,4,6]. Considering the promising results in lymphocytic and myeloid 
leukemia, and the hematotoxic side effects in humans with solid tumors, CPEC might be of use in 
the treatment of ALL. As shown by our results using a xenogeneic in vivo model for ALL, efficacy 
was associated with severe toxicity (chapter 5). In earlier studies an increase in life span upon 
CPEC treatment was demonstrated. There might be several explanations for the different results 
between our study and the earlier in vivo studies. First, as we continuously monitored leukemic 
progression and toxicity, we were able to determine the actual response during treatment instead 
of having death as the only evaluation point for efficacy and toxicity. Moreover, in our model 
leukemic progression could be excluded as a possible cause of death, allowing discrimination 
between activity and toxicity of therapy. Secondly, we started treatment from the moment that 
leukemic cells could be detected and not immediately after inoculation. The third explanation 
might be that we administrated human leukemic cells whereas earlier studies used cells of murine 
origin which might respond differently to CPEC. 
In leukemia combination therapy is frequently used. Reasons for this strategy might be to create 
synergy between drugs by acting via multiple pathways or reduction of toxicities by lowering the 
dose of the individual drugs. Regarding CPEC, cytarabine seems to be a logical candidate for 
combination therapy as the uptake and therefore activity of cytarabine is regulated by feedback 
inhibition of deoxy-CTP (dCTP). As CPEC can deplete CTP and therefore dCTP, it might be 
responsible for enhanced activity of cytarabine. Our in vitro results suggest an additive but not 
synergistic effect of CPEC and cytarabine. Therefore we chose not to investigate the combination 
treatment of CPEC and cytarabine in our in vivo animal model for human ALL. However, even 
if no synergistic effect can be accomplished, it might be interesting to investigate whether a 
combination of cytarabine and low dose CPEC will reach similar efficacy when compared to the 




As survival and cure rates for cancer increase, reduction and management of side effects become 
more important. Cardiotoxicity is an important problem associated with current chemotherapeutic 
regimens (chapter 6). Moreover, this is not exclusively a problem of the classic cytotoxic drugs, as 
several studies report cardiotoxic side effects after treatment with the newer targeted drugs. The 
monoclonal antibody trastuzumab and recently also imatinib and sunitinib [7-9] are examples of 
newer cytostatic drugs associated with cardiotoxicity. As shown in the case of CPEC, cardiotoxic 
side effects might hamper the introduction of potentially interesting drugs. It would be interesting 
to know why in particular the heart is susceptible to toxic side effects and how these effects can 
be prevented or predicted.
Mechanism
When taking a better look at anthracycline induced cardiotoxicity, it becomes clear that these 
answers are not so easily found. Although extensive research has been undertaken to study 
anthracycline induced cardiotoxicity, the mechanism is not completely clarified. Reactive oxygen 
radicals are supposed to play an important role and it has been postulated that due to a low level 
of antioxidant enzymes (e.g. SOD), the heart would be more susceptible to the destructive action of 
these radicals [10]. Following this theory antioxidant therapy might be useful; however, until now 
there have been no antioxidants that have been able to yield good results against anthracycline 
induced cardiotoxicity. In the anti-oxidative theory iron plays an important role as it is believed 
to form a free radical complex with reduced anthracyclines. The iron chelator dexrazoxane can 
bind iron and thereby prevent or reduce the formation of the complex. Dexrazoxane has shown 
promising results in preventing cardiotoxicity and is currently the only agent approved for the 
prevention of anthracycline induced cardiotoxicity [11,12]. It was also suggested that apoptosis 
plays a role and indeed doxorubicin treated mice showed an increased apoptotic rate in their 
hearts [13]. 
When studying the cardiotoxic effects of CPEC, we used an anthracycline based approach in 
our attempts to clarify its cardiotoxic effects (chapter 7). There are a few objections to be made 
against this approach. First, CPEC does not have a structural relationship with anthracyclines 
and from that point of view a similarity in mechanism might not be logical. Secondly, the 
observed hypotension after treatment with CPEC is not a common cardiotoxic side effect seen 
with anthracyclines. However, as anthracycline induced cardiotoxicity has been known for years, 
many models have been developed and validated to study this phenomenon. These models might 
therefore also be suitable for studying the side effects of other drugs. Moreover, in our animal model 
we studied a general phenomenon (apoptosis) that is also associated with CPEC treatment. We 
have not been able to detect CPEC induced apoptosis in rats. It is possible that some physiological 
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aspects of rats might have played a role in the absence of cardiotoxicity of CPEC in our study. 
Rats are reported to have very low levels of cytidine deaminase, the enzyme responsible for 
the deamination of cytidine to uridine. This might lead to high levels of cytidine which have 
been suggested to protect against CPEC induced toxicity. However, cytidine deaminase is also 
responsible for the deamination of CPEC to CPEU, and it is not known what ratio of CPEC-cytidine 
levels is necessary for efficacy or toxicity. Moreover, although we did not study it as extensively as 
in rats, we also could not demonstrate signs of cardiotoxicity in mice, which are reported to have 
cytidine deaminase activities comparable to humans [14,15].
Prevention and prediction
In current practice restricting the total cumulative dose, reducing peak levels, delivering the 
anthracycline in liposomes or administration of a protective agent (dexrazoxane) are the most 
effective tools to prevent cardiotoxicity. Although dose restriction might be easy to undertake, 
it is not always desirable and there are still patients (up to 5%) with cardiotoxicity despite the 
administration of lower doses, as well as patients that do not encounter any problems even after 
very high dosage of anthracyclines. 
Moreover, the measures currently taken all seem to merely attempt to lower the total exposure 
of the drug to heart cells without understanding differences in individual sensitivity. It therefore 
becomes more important to be able to predict which patients are prone to chemotherapy induced 
cardiotoxicity. 
The individual differences might indicate that there is a role for pharmacogenetics in chemotherapy 
induced cardiotoxicity. The study by Wojnowski et al is the first study to report an association 
between single nucleotide polymorphisms (SNPs) and anthracycline induced cardiotoxicity [16]. 
In this study a candidate gene approach is used and the investigators report an association with 
cardiotoxicity for six SNPs in five genes. The associated SNPs are located in genes involved in 
either NAD(P)H oxidase (p22phox, p40phox, Rac2) or doxorubicin efflux transporters (MRP1, 
MPR2). As described in chapter 8 we have demonstrated that the expression of MRP1 in rat 
cardiomyocyte cells decreased by doxorubicine and the expression of MRP2 showed a small 
decrease after incubation with CPEC. No changes in expression were observed for the other genes 
studied. Information on the influence of doxorubicin or CPEC on expression of the candidate 
genes might help in understanding the role of the gene and the specific SNP and their possible 
association with chemotherapy induced cardiotoxicity. Furthermore we have been able to reproduce 
the association between a polymorphism in the GTPase Rac2 which is essential for the function 
of the NAD(P)H oxidase multi-enzyme complex and cardiotoxicity of doxorubicin in a case control 
study. Sample size might have been an important reason for the absence of an association for 
the other five SNPs in our study. However, this is also an illustration of an important problem 
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for the clinical use of screening for these SNPs in anthracycline induced cardiotoxicity. Even if 
we would have been able to increase our sample size and could have reproduced the findings of 
the previous study, the frequency of overt anthracycline induced cardiotoxicity would still be low 
(1.1% in our study). Therefore, in order to identify patients with the associated SNPs, the ‘number 
needed to genotype’ would be unrealistically high. Moreover, as demonstrated by Wojnowski 
et al only 7-29% of the cases could be attributed to the carrier status of one of the candidate 
genes [16]. This implicates that knowledge of a cardiotoxicity associated SNP of a patient will 
only partly help in predicting whether this patient will ultimately develop anthracycline induced 
cardiotoxicity. Nevertheless, when combining genetic variants with other known risk factors, such 
algorithms or predictive models may prove a useful tool in the prediction of chemotherapy induced 
cardiotoxicity. 
CONCLUSION AND FUTURE ASPECTS 
In conclusion, the results presented in this thesis show that CPEC might not have fulfilled all of its 
promises. Single agent therapy in ALL proved to have a therapeutic window too small for further 
development. However, it cannot be ruled out that combination therapy in other hematological 
or solid tumors might be an useful addition to current therapeutic regimens. Positive findings 
are that in the studied animal models no further indications for CPEC induced cardiotoxicity 
were found. However, the results of the first study in patients experiencing severe hypotension 
cannot be neglected. This implicates that if CPEC is administrated in experimental protocols 
to patients, monitoring of cardiac function remains necessary. Unfortunately, cardiotoxicity is 
common among cytotoxic drugs and the vast amount of studies undertaken with anthracycline 
induced cardiotoxicity demonstrate that solutions to resolve the problem are not easily found. 
With the increasing possibilities of pharmacogenetics, a new modality might have become 
available. Although pharmacogenetics will not provide an absolute answer, combining our existing 
knowledge of risk factors with new genetic findings might bring us closer to good management of 
chemotherapy induced cardiotoxicity. 
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In this thesis pharmaceutical aspects as well as anti-tumor activity and cardiotoxicity of the 
experimental cytostatic drug cyclopentenyl cytosine (CPEC) are explored. CPEC is derived from the 
nucleoside neplanocin A and structurally related to the clinically used cytostatic drugs cytarabine 
and gemcitabine.
By inhibiting the enzyme CTP-synthetase (cytidine triphosphate synthetase), CPEC decreases 
the ‘de novo’ synthesis of CTP from UTP (uridine triphosphate), resulting in depleted CTP pools. 
CTP can also be generated from the so called ‘salvage pathway’ out of cytidine. However, several 
malignancies have been shown to predominantly use the ‘de novo synthesis’ involving CTP 
synthetase. A depletion of CTP pools may ultimately lead to death as a result of impaired RNA 
and DNA synthesis and S-phase accumulation, resulting in cell death. 
In chapter 2 an overview is given of the studies undertaken with CPEC. Originally the drug was 
selected out of several analogues of neplanocin A based on its antiviral properties and indeed in 
vitro studies show activity against a wide range of viruses. However, its anti-tumor activity was 
considered more interesting for further development and no animal or human studies have been 
undertaken to investigate its antiviral properties. 
CPEC has been most extensively studied in hematological malignancies and several in vitro and 
in vivo studies show activity of CPEC against leukemia. Other promising results were achieved in 
models for colorectal carcinoma and neuroblastoma. 
There is one clinical trial published using CPEC in a phase I study in patients with solid 
tumors. Besides dose limiting hematological side effects, the most severe toxicity observed was 
cardiovascular. This side effect was seen in the higher dose groups. 
As new trials with low dose CPEC were planned and only the raw substance was available, there 
was a need for a pharmaceutical formulation of CPEC. In chapter 3 we describe the development 
of a stable sterile infusion concentrate that can be easily administered. 
Because the cardiotoxicity as observed in the phase I trial was thought to be related to high 
CPEC plasma levels, therapeutic drug monitoring was considered to be necessary in future trials. 
In chapter 4 a HPLC-MSMS method is described which enabled us to quantitatively determine 
low levels of CPEC. Although not at levels as low as CPEC, its metabolite CPEU (cyclopentenyl 
uridine), could also be detected with this method. CPEU is not thought to have anti-tumor activity 
and its plasma levels did not seem to be related with cardiotoxicity in the phase I study. Therefore, 
the higher limit of detection for CPEU was not considered as a problem for the use of the method 
in clinical trials. 
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Several in vivo studies showed promising activity of CPEC in leukemia. However, these studies 
used murine leukemic cells and no data were available with human leukemic cells. In chapter 5 we 
analyzed the activity of CPEC on human acute lymphoblastic leukemia (ALL) cell lines in vitro, as 
well as on corresponding human primary ALL cells in a xenogeneic in vivo model using NOD/scid 
mice. Our in vitro results on five different human cell lines show activity of CPEC in the nanomolar 
range (IC50 6-15nM). 
Based on their mechanisms of action and earlier in vitro results, combination therapy of CPEC with 
the cytotoxic drug cytarabine was suggested to have a synergistic effect. However, we detected 
no such effect on our leukemic cell lines after coincubation with CPEC and cytarabine. Therefore, 
single agent therapy with CPEC was studied in the NOD/scid mice inoculated with primary human 
ALL cells. Whereas no activity nor toxicity was seen in the lower dose ranges (0.5 mg/kg for 2 or 5 
days per week) a marginal anti-leukemic activity was observed at 1.5 mg/kg (5 days per week) and 
5 mg/kg (2 days per week), however, this activity was associated with severe systemic toxicity. 
In the phase I study with CPEC the most severe side effect was cardiovascular. Cardiotoxicity 
induced by cytotoxic drugs is unfortunately not uncommon and in chapter 6 several classes of 
cytotoxic drugs that have been associated with cardiotoxicity are reviewed. Anthracyclines are well 
known for this toxicity and its mechanism has been extensively studied. Oxidative stress seems to 
play an important role, however, apoptosis, genetic causes and influence on calcium homeostasis 
might also be involved. Prevention mainly consists of restricting the maximum cumulative dose 
and avoiding peak levels. Alternatively administration of a liposomal formulation or addition of a 
protective agent can be applied. However, none of these measures offer full protection. 
Although not as frequently as anthracyclines, other cytotoxic drugs associated with cardiotoxicity 
are 5-fluorouracil, cyclophosphamide, cisplatin and more recently trastuzumab, imatinib and 
sunitinib. 
The mechanism behind the severe hypotension associated with CPEC in the phase I trial had not 
been clarified. Before initiating clinical studies with CPEC it was necessary to investigate if the 
cardiotoxicity could be reproduced and what might have been the mechanism. In chapter 7 we 
first studied the effects of CPEC on contraction force and frequency in a model using isolated atria 
of male Wistar rats. No changes in frequency were detected and although a trend in decrease 
of contraction force was observed, the differences were not significant. Our second hypothesis 
focused on the possible induction of apoptosis in the heart by CPEC. In an in vivo model we 
administrated CPEC to male Wistar rats and evaluated the presence or absence of apoptosis by 
99mTc-AnnexinV scintigraphy, followed by postmortem determination of radioactivity in tissues, 
and histological confirmation. This model had been used before to demonstrate the apoptosis 
inducing potential of doxorubicin. We detected no increase in cardiac uptake of 99mTc-AnnexinV 
after treatment with CPEC, thereby having no indications for increased apoptosis in the heart. 
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Summary
With the models described in chapter 7 we only studied a few aspects that might have an 
association with cardiotoxicity. In chapter 8 we investigated whether cardiotoxicity induced by 
cytotoxic drugs might have a genetic origin. Even in the case of anthracycline induced cardiotoxicity 
little is known about the role of genetics. We first attempted to reproduce the results of a previous 
study reporting an association between single nucleotide polymorphisms (SNPs) and doxorubicin 
induced cardiotoxicity. SNPs in genes related to the NAD(P)H oxidase enzyme complex (p22phox, 
p40phox and Rac2) and the drug efflux pumps MRP1 and MRP2 were investigated. We were able 
to reproduce the association between a SNP in Rac2 and anthracycline induced cardiotoxicity. No 
other associations were observed, which might have been caused by the relatively small size of 
our group of patients with anthracycline induced cardiotoxicity. 
The role of the candidate genes was further explored by studying changes in expression after 
exposing rat cardiomyocytes to doxorubicin and CPEC. No changes in expression were seen for 
the genes involved in the NAD(P)H oxidase enzyme complex. However, after 24 hr of incubation 
doxorubicin decreased the expression of the MRP1 gene and CPEC seemed to induce a small 
decrease in the expression of MRP2. 
Based on the association with the SNP in Rac2 and the decrease in expression in MRP1 and 
MRP2, we concluded that genetic aspects of the NAD(P)H oxidase enzyme complex and the efflux 
pumps may be involved in cytostatic drug induced cardiotoxicity. 
In chapter 9 the results from the studies in this thesis are discussed and future aspects are 
indicated. Although CPEC as a single agent in our leukemic in vivo model did not fulfill its 
promises, we believe that this agent might still have potential in combination with other agents 
in several malignancies. Its possible cardiotoxic side effects could not be reproduced in an animal 
model. 
As demonstrated by the results of our last study cardiotoxicity of cytotoxic drugs might also 
have genetic aspects. However, we only studied expression profiles of a few genes and it is not 
unlikely that a vast amount of other genes might be involved as well. Moreover, the frequency 
of clinically overt cardiotoxicity is relatively low, indicating that a high number of patients would 
have to be genotyped in order to identify patients at risk. Therefore it may be concluded that 
pharmacogenetics will not provide an absolute answer but may be a valuable addition to the 
existing tools for the management of chemotherapy induced cardiotoxicity.
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In dit proefschrift worden zowel farmaceutische aspecten als ook anti-tumor activiteit en 
cardiotoxiciteit van het cytostaticum cyclopentenyl cytosine (CPEC) onderzocht. CPEC is afgeleid 
van het nucleoside neplanocine A en lijkt voor wat betreft de chemische structuur op de klinisch 
gebruikte cytostatica cytarabine en gemcitabine. CPEC remt het enzym CTP-synthetase (cytidine 
trifosfaat synthetase), hierdoor vermindert de zogenoemde ‘de novo synthese’ van CTP uit UTP 
(uridine trifosfaat). Dit leidt tot uitputting van de CTP voorraden in de cel. CTP kan ook uit cytidine 
worden gemaakt, via de ‘salvage pathway’. Het blijkt echter dat verschillende maligniteiten vooral 
de ‘de novo synthese’ route volgen waarbij gebruik wordt gemaakt van CTP synthetase. Een 
uitputting van de CTP voorraden kan uiteindelijk leiden tot celdood door problemen met RNA- en 
DNA-synthese en stoppen van de celcyclus in de S-fase. 
In hoofdstuk 2 wordt een overzicht gegeven van de verschillende studies die met CPEC hebben 
plaatsgevonden. Oorspronkelijk was het geneesmiddel geselecteerd uit een groep van analoga van 
neplanocine A vanwege zijn antivirale eigenschappen zoals ook later is aangetoond in verschillende 
in vitro studies. De mogelijke anti-tumor effecten werden echter als interessanter beschouwd en er 
zijn geen studies naar het antivirale effect uitgevoerd in dieren of mensen.
Het effect van CPEC in hematologische maligniteiten is het meest onderzocht en verschillende 
in vitro en in vivo studies laten een anti-leukemisch effect van CPEC zien. Andere veelbelovende 
preklinische resultaten zijn behaald op het gebied van darmkanker en neuroblastomen. 
Er is één fase I studie gepubliceerd waarin CPEC onderzocht is bij mensen met solide tumoren. 
Naast dosisbeperkende hematologische bijwerkingen, was de ernstigste bijwerking die optrad 
cardiovasculair. Deze bijwerking trad op bij patiënten in de hogere doseringsgroepen. 
Aangezien nieuwe klinische studies met CPEC (in een lage dosering) zouden worden uitgevoerd 
en alleen de grondstof beschikbaar was, was er behoefte aan een farmaceutische formulering van 
CPEC. In hoofdstuk 3 wordt de ontwikkeling beschreven van een stabiel en steriel infuusconcentraat 
dat gemakkelijk kan worden toegediend. 
De cardiotoxiciteit die in de fase I studie optrad leek een relatie te hebben met hoge plasma spiegels 
van CPEC en controle van de bloedspiegels werd daarom noodzakelijk geacht. In hoofdstuk 4 wordt 
een HPLC-MSMS methode beschreven waarmee lage CPEC spiegels nauwkeurig gemeten konden 
worden. CPEU (cyclopentenyl uridine), de metaboliet van CPEC, kon ook met deze methode 
worden bepaald, zij het in hogere concentraties. CPEU heeft waarschijnlijk geen anti-tumor 
effecten en CPEU spiegels werden in de fase I studie niet in verband gebracht met cardiotoxiciteit. 
Voor de toepassing van de methode in klinische studies lijkt de hogere bepalingslimiet van CPEU 
dan ook geen consequenties te hebben. 
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Op het gebied van leukemie hebben verschillende preklinische studies goed resultaat van CPEC 
laten zien. Al deze studies zijn echter uitgevoerd met leukemie cellen van muizen oorsprong en 
er waren geen gegevens beschikbaar met humane leukemie cellen. In hoofdstuk 5 hebben we de 
activiteit van CPEC op humane acute lymfoblastische leukemie (ALL) cellijnen in vitro bestudeerd. 
Daarnaast is het effect van behandeling met CPEC bekeken in NOD/scid muizen die humane 
primaire ALL cellen hadden gekregen. 
Op basis van de in vitro resultaten leek CPEC activiteit te hebben in het nanomolaire gebied: 50% 
van de cellen overleed (IC50) bij doseringen tussen de 6 en 15 nM.
Op basis van het werkingsmechanisme en eerdere in vitro resultaten, zou combinatie therapie 
van CPEC en het cytostaticum cytarabine een synergistisch effect kunnen hebben. Een dergelijk 
effect kon echter niet worden aangetoond in onze leukemie cellen na co-incubatie met CPEC 
en cytarabine. Er is daarom besloten om in het muizenmodel alleen het effect van CPEC te 
onderzoeken en geen combinatietherapie. In de lagere dosisgroepen (0.5 mg/kg gedurende 2 of 
5 dagen per week) werd noch een anti-leukemisch noch een toxisch effect gezien. Een klein anti-
leukemisch effect trad op na 1.5 mg/kg (5 dagen per week) en 5 mg/kg (2 dagen per week), dit 
effect ging echter gepaard met ernstige systemische toxiciteit. 
In de fase I studie met CPEC was cardiotoxiciteit de ernstigste bijwerking. Helaas komt cardiotoxiciteit 
vaker voor bij de behandeling met chemotherapie en in hoofdstuk 6 worden verschillende 
cytostatica besproken waarbij dit effect kan optreden. Anthracyclines zijn hier vooral berucht 
om en veel studies zijn uitgevoerd om het mechanisme te achterhalen. Hoewel oxidatieve stress 
een belangrijke rol lijkt te spelen, worden ook apoptose (geprogrammeerde celdood), genetische 
oorzaken en invloed op de calcium regulering met anthracycline geïnduceerde cardiotoxiciteit in 
verband gebracht. Preventie bestaat voornamelijk uit het beperken van de cumulatieve dosering 
en het vermijden van hoge piek spiegels. Andere maatregelen kunnen bestaan uit het toedienen 
van het anthracycline in een liposomale vorm of het toevoegen van een beschermend middel aan 
de behandeling. Geen van de genoemde maatregelen biedt echter volledige bescherming. 
Hoewel minder vaak voorkomend dan bij anthracyclines, wordt cardiotoxiciteit ook wel gezien 
bij 5-fluorouracil, cyclofosfamide, cisplatin en de nieuwere middelen trastuzumab, imatinib en 
sunitinib.
De oorzaak van het optreden van de ernstige hypotensie na behandeling met CPEC in de fase 
I studie is niet bekend. Voordat nieuwe studies met CPEC zouden kunnen starten, was het 
noodzakelijk om hier meer onderzoek naar te verrichten. In hoofdstuk 7 hebben we eerst gekeken 
naar de effecten van CPEC op contractiekracht en frequentie in een model waarbij geïsoleerde 
atria (hartboezems) van mannelijke Wistar ratten werden gebruikt. Er traden geen veranderingen 
in hartfrequentie op en ondanks dat er een trend in daling van de contractiekracht werd gezien, 
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het verschil in contractiekracht tussen behandelde en onbehandelde atria niet significant. In 
een in vivo model is vervolgens CPEC toegediend aan mannelijke Wistar ratten en de aan- of 
afwezigheid van apoptose bestudeerd door middel van scintigrafie met 99mTc-Annexine V, 
gevolgd door postmortem radioactiviteits-telling van de organen en histologisch onderzoek. Dit 
diermodel was in een eerdere studie toegepast om de apoptose inducerende eigenschappen van 
doxorubicine te onderzoeken. De resultaten van onze studie lieten geen verhoging van hartopname 
van Tc99mAnnexine V zien, zodat er geen aanwijzingen waren dat CPEC apoptose in het hart 
veroorzaakt. 
Met de modellen die in hoofdstuk 7 zijn beschreven, zijn slechts een paar aspecten die met 
cardiotoxiciteit te maken kunnen hebben, bestudeerd. In hoofdstuk 8 is onderzocht of cytostatica 
geïnduceerde cardiotoxiciteit ook een genetische oorzaak kan hebben. Zelfs in het geval van 
de anthracyclines is weinig bekend in hoeverre genetische oorzaken een rol spelen bij de 
cardiotoxiciteit. 
Allereerst is gekeken of de resultaten konden worden herhaald van een studie die een verband had 
beschreven tussen SNPs1 en doxorubicine geïnduceerde cardiotoxiciteit. Het betrof SNPs in genen 
die een relatie hadden met het NAD(P)H-oxidase enzym complex (p22phox, p40phox en Rac2) en 
de geneesmiddel efflux pompen MRP1 en MRP2. In onze studie hebben we de associatie tussen 
de SNP in Rac2 en anthracycline geïnduceerde cardiotoxiciteit kunnen bevestigen. De andere 
associaties konden niet worden aangetoond, vermoedelijk speelde de relatief kleine groepsgrootte 
daarbij een rol. 
De mogelijke invloed van de kandidaat genen is vervolgens verder onderzocht door naar 
expressieveranderingen te kijken in rat cardiomyocyten na behandeling met doxorubicine of 
CPEC. De expressie veranderde niet voor de genen die een relatie hadden met het NAD(P)H-
oxidase enzym complex. Na 24 uur incubatie met doxorubicine werd echter wel een afname in 
de expressie van MRP1 gezien. CPEC leek na 24 uur een kleine daling in de expressie van MRP2 
te veroorzaken. 
Gebaseerd op de associatie met de SNP in Rac2 en de expressie veranderingen in MRP1 en 
MRP2, is geconcludeerd dat zowel genetische aspecten van het NAD(P)H oxidase enzym complex 
als van de effluxpompen een rol lijken te spelen bij cytostatica geïnduceerde cardiotoxiciteit.
In hoofdstuk 9 worden de voorgaande hoofdstukken bediscussieerd en mogelijke toekomstige 
richtingen voor onderzoek aangegeven. Hoewel wat betreft anti-tumor activiteit CPEC in het in vivo 
leukemie model niet aan de verwachtingen heeft voldaan, is het niet ondenkbaar dat dit middel 
mogelijk een toepassing kan hebben in de combinatie met andere middelen in verschillende 
maligniteiten. De mogelijke cardiotoxiciteit is in het diermodel niet bevestigd.
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Zoals aangetoond in de laatste studie lijken genetische aspecten een rol te kunnen spelen bij 
cytostatica geïnduceerde cardiotoxiciteit. In deze studie zijn echter maar enkele genen bestudeerd 
en het is niet onwaarschijnlijk dat een groot aantal andere genen ook een rol speelt. Daarnaast 
is de frequentie van klinisch relevante cardiotoxiciteit relatief laag, hetgeen ertoe zou leiden dat 
het genotype van een groot aantal patiënten bepaald zou moeten worden om risicopatiënten te 
kunnen identificeren.
Farmacogenetica zal dan ook vermoedelijk niet in staat zijn om de volledige oplossing voor het 
probleem te kunnen geven, maar kan mogelijk wel een goede aanvulling zijn bij de huidige 
maatregelen die worden genomen in het voorkomen en behandelen van cytostatica geïnduceerde 
cardiotoxiciteit. 




Het is zover, het boekje is klaar. Van vele kanten heb ik hulp gekregen en een woord van dank is 
dan ook zeker op zijn plaats. Het is onmogelijk om volledig te zijn, maar ik zou er toch graag een 
aantal personen uit willen lichten. 
Het begon allemaal in Amsterdam. Dankzij de inbreng van de medewerkers van de apotheek van 
het AMC is er een injecteerbare vorm van CPEC gekomen. Erik wil ik in het bijzonder bedanken 
voor zijn bijdrage hierin. Roel, Formijn en Cora, bedankt voor jullie hulp bij het ‘nucleaire’ deel 
van het onderzoek. 
De hulp van Andre en René van het laboratorium voor genetisch metabole ziekten, is onmisbaar 
geweest, bedankt hiervoor.
Na Amsterdam volgde Leiden en ook daar heb ik weer dankbaar gebruik gemaakt van de hulp van 
velen. Professor Falkenburg, Bart en Marianke wil ik bedanken voor de hulp bij het bestuderen van 
CPEC in het NOD/scid muizen model van de experimentele hematologie. 
Farmacogenetica mocht natuurlijk niet ontbreken en Tahar, Judith en Chris hebben er mede voor 
gezorgd dat dit mogelijk was, bedankt hiervoor.
Zonder belangstelling en de gelegenheid om me vrij te maken voor onderzoek naast het ‘gewone’ 
werk, was promoveren onmogelijk geweest. Alle medewerkers van de apotheek van het LUMC wil 
ik dan ook bedanken. Erica en Gert in het bijzonder, mede doordat jullie mijn onderzoeksdag soms 
nog beter bewaakten dan ikzelf, is het gelukt om het af te maken. 
Dank ook aan mijn paranimfen. Dinemarie, samen roeien hebben we maar even gedaan, maar 
samenwerken doen we hopelijk nog lange tijd. Ingrid, mijn ‘grote’ zus, ook bij deze belangrijke 
gebeurtenis in mijn leven ben je er gelukkig weer bij. 
Alle vrienden, bedankt voor de gezelligheid, het vragen naar de vorderingen, maar ook juist niet 
als het even ‘verboden onderwerp’ was.
Pap en mam, bedankt voor jullie steun die er altijd is. 
Vincent, de laatste in de rij, maar ook de belangrijkste factor in mijn leven. Zowel aan je motiverende 
als ook relativerende eigenschappen heb ik de afgelopen onderzoeksjaren veel gehad. Rustige 
tijden zullen nu vast niet aanbreken, maar genieten zullen we zeker...
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